STOCK TITAN

22nd Century Group flags going-concern doubt

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Moderate)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
10-Q

Rhea-AI Filing Summary

22nd Century Group, Inc. (XXII) reported third-quarter 2026 revenue of $4.759 million, up from $4.011 million a year earlier, and gross profit of $446,000 versus a $1.059 million gross loss. Net loss from continuing operations narrowed to $2.564 million from $3.763 million. For the first nine months, revenue fell to $11.729 million from $14.050 million, while net loss from continuing operations was $8.848 million, compared with $10.333 million.

Cash used in operating activities was $8.636 million for the nine months, and cash and cash equivalents were $3.911 million as of September 30, 2026. The company said these resources and its projected operating requirements raise substantial doubt about its ability to continue as a going concern through one year after the financial statements are issued; management’s plans do not alleviate that doubt.

Through November 13, the company had sold 3,151,300 shares through its at-the-market program for $10.536 million in gross proceeds and $10.138 million net. It used $5.576 million to redeem Series B preferred shares, leaving 2,929 Series B preferred shares outstanding.

4 points · 0 major

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

1 major · 2 points

How the balance works

Positive

  • Moderate pointThird-quarter revenue rose 18.6% to $4.759 million.
  • Moderate pointQuarterly gross profit reached $446,000, versus a $1.059 million gross loss a year earlier.
  • Moderate pointNine-month continuing-operations loss narrowed 14.4% to $8.848 million.
  • Moderate pointOperating cash use decreased $1.836 million to $8.636 million.

Negative

  • Major pointSubstantial doubt remains about the company’s ability to continue as a going concern through one year after the statements are issued.
  • Moderate pointNine-month revenue fell 16.5% to $11.729 million.

Filing Explained

The 1-for-58 split is complete, while about $13,000 thousand of ATM sale capacity remains available rather than representing another completed share sale.

22nd Century Group reports completing a 1-for-58 reverse stock split on November 5, 2026 to regain Nasdaq continued-listing compliance; the number of additional shares from fractional-share rounding is still pending final determination.

A reverse split consolidates shares, reducing the share count and proportionally raising the per-share price; the split itself does not change company value.

As of November 13, 2026, approximately $13,000 thousand of ATM capacity remained; the program permits gradual share sales at prevailing market prices, so this is capacity, not shares already issued or a commitment to issue them.

Third-quarter net revenue $4.759 million Three months ended September 30, 2026; $4.011 million in the prior-year period
Nine-month net revenue $11.729 million Nine months ended September 30, 2026; $14.050 million in the prior-year period
Third-quarter gross profit $446,000 Three months ended September 30, 2026; compared with a $1.059 million gross loss in 2025
Third-quarter net loss from continuing operations $2.564 million Three months ended September 30, 2026; compared with $3.763 million in 2025
Nine-month net loss from continuing operations $8.848 million Nine months ended September 30, 2026; compared with $10.333 million in 2025
Cash used in operating activities $8.636 million Nine months ended September 30, 2026; compared with $10.472 million in 2025
Cash and cash equivalents $3.911 million As of September 30, 2026
ATM net proceeds $10.138 million Common stock sales through the at-the-market program as of November 13, 2026
Modified Risk Tobacco Product regulatory
"FDA Modified Risk Tobacco Product authorization"
A modified risk tobacco product is a tobacco or nicotine product that is marketed with claims it reduces health risks or exposure to harmful substances compared with other tobacco products; such claims are typically subject to regulatory review and approval. For investors, this matters because approved modified-risk status can change consumer demand, legal exposure, labeling requirements and market access—similar to how a government-backed “low-risk” label can alter a product’s sales and liability profile.
going concern financial
"substantial doubt about the Company’s ability to continue as a going concern"
Going concern is the accounting assumption that a company will keep operating and meeting its obligations for the foreseeable future. The phrase matters most when a company or its auditors disclose substantial doubt about it, a formal warning that the business may not have enough resources to continue without raising money, restructuring, or selling assets. That language in a filing or press release signals elevated financial risk.
mezzanine equity financial
"classified as “mezzanine equity” (temporary equity)"
Mezzanine equity is a layer of financing that sits between bank loans and full ownership, combining elements of borrowed money and equity. It often gives lenders higher potential returns in exchange for taking more risk, sometimes with the option to convert into ownership or receive extra payments; think of it as a middle seat that pays more because it’s less secure than front-row debt. Investors watch it because it affects a company’s debt risk, potential dilution of ownership, and expected returns.
Alternative Conversion Price financial
"the “Alternative Conversion Price”"
cashless basis financial
"all of the June 2026 Inducement Warrants to be exercised on a cashless basis"
An agreement executed on a cashless basis lets a holder convert or exercise a security (like options, warrants, or conversion rights) without paying money upfront; instead the holder receives a smaller number of shares equal in value to what the cash would have purchased. Think of trading a coupon for fewer slices of a cake rather than handing over cash for the full slice. For investors, it affects how much ownership and dilution occur and avoids immediate cash outlays.
at-the-market common equity offering program financial
"at-the-market common equity offering program"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How did XXII perform in the third quarter of 2026?

XXII reported third-quarter revenue of $4.759 million, compared with $4.011 million in 2025, and gross profit of $446,000, versus a $1.059 million gross loss. Net loss from continuing operations was $2.564 million, compared with $3.763 million a year earlier.

What did XXII report about its ability to continue as a going concern?

The company reported $3.911 million in cash and cash equivalents as of September 30, 2026, and $8.636 million of cash used in operating activities for the nine months ended then. It said substantial doubt remains through one year after the financial statements are issued, and management’s plans do not alleviate that doubt.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
0001347858--12-312026Q3false0.06670.05000.01720.04350.06670.05000.01720.04350.06670.05000.0173http://www.xxiicentury.com/20260930#GvbbiopharmaMember10.05000001347858us-gaap:CommonStockMember2026-07-012026-09-300001347858us-gaap:CommonStockMember2026-01-012026-09-300001347858us-gaap:SeriesBPreferredStockMemberxxii:March2026SeriesBConvertiblePreferredStockOfferingTrancheTwoMember2026-03-200001347858xxii:June2026InducementWarrantsMember2026-08-132026-08-130001347858xxii:GvbPromissoryNote2025Member2025-09-180001347858xxii:NeedleRockFarmsLandPropertyMember2025-01-012025-09-300001347858xxii:GvbPromissoryNote2023Member2025-01-012025-09-300001347858us-gaap:PatentsMember2026-07-012026-09-300001347858us-gaap:PatentsMember2026-01-012026-09-3000013478582025-12-172025-12-170001347858srt:MaximumMember2026-01-012026-09-300001347858xxii:June2026InducementWarrantsMember2026-06-082026-06-080001347858xxii:June2026InducementWarrantsMember2026-06-122026-06-120001347858xxii:PipeWarrantsAndPipePlacementAgentWarrants2024Member2025-04-292025-04-290001347858us-gaap:SubsequentEventMemberxxii:AtMarketOfferingMember2026-11-130001347858us-gaap:SubsequentEventMemberxxii:AtMarketOfferingMember2026-10-230001347858xxii:AtMarketOfferingMember2026-05-0100013478582026-05-010001347858xxii:AtMarketOfferingMember2025-11-040001347858us-gaap:SeriesBPreferredStockMemberxxii:March2026SeriesBConvertiblePreferredStockOfferingMember2026-03-202026-03-200001347858xxii:August2025PreferredStockWarrantsMemberxxii:August2025SeriesaConvertiblePreferredStockOfferingMember2025-08-220001347858us-gaap:SeriesAPreferredStockMember2025-07-012025-09-300001347858us-gaap:SeriesAPreferredStockMember2026-09-300001347858us-gaap:SeriesAPreferredStockMember2026-06-300001347858us-gaap:SeriesAPreferredStockMember2026-03-310001347858us-gaap:SeriesAPreferredStockMember2025-12-310001347858us-gaap:SeriesAPreferredStockMember2025-09-300001347858us-gaap:SeriesAPreferredStockMember2025-06-300001347858us-gaap:SeriesAPreferredStockMember2025-03-310001347858us-gaap:SeriesAPreferredStockMember2024-12-3100013478582026-03-242026-03-240001347858us-gaap:SeriesBPreferredStockMemberus-gaap:AdditionalPaidInCapitalMember2026-06-082026-06-080001347858us-gaap:SeriesAPreferredStockMember2026-03-242026-03-240001347858us-gaap:SeriesAPreferredStockMember2026-01-012026-03-310001347858us-gaap:AdditionalPaidInCapitalMember2026-07-012026-09-300001347858us-gaap:AdditionalPaidInCapitalMember2026-04-012026-06-300001347858us-gaap:AdditionalPaidInCapitalMember2026-01-012026-03-310001347858us-gaap:AdditionalPaidInCapitalMember2025-04-012025-06-300001347858us-gaap:SeriesBPreferredStockMemberus-gaap:AdditionalPaidInCapitalMember2026-04-012026-06-300001347858us-gaap:SeriesBPreferredStockMemberus-gaap:PreferredStockMemberxxii:AtMarketOfferingMember2026-01-012026-03-310001347858us-gaap:SeriesBPreferredStockMemberus-gaap:AdditionalPaidInCapitalMember2026-01-012026-03-310001347858us-gaap:AdditionalPaidInCapitalMemberxxii:AtMarketOfferingMember2026-01-012026-03-310001347858us-gaap:AdditionalPaidInCapitalMember2025-07-012025-09-300001347858us-gaap:AdditionalPaidInCapitalMember2025-01-012025-03-310001347858us-gaap:CommonStockMember2025-07-012025-09-300001347858us-gaap:CommonStockMember2025-04-012025-06-300001347858us-gaap:SeriesBPreferredStockMemberxxii:March2026SeriesBConvertiblePreferredStockOfferingTrancheTwoMember2026-03-202026-03-200001347858us-gaap:SeriesBPreferredStockMemberxxii:March2026SeriesBConvertiblePreferredStockOfferingTrancheOneMember2026-03-202026-03-200001347858us-gaap:CommonStockMemberxxii:AtMarketOfferingMember2026-01-012026-03-310001347858us-gaap:CommonStockMember2026-04-012026-06-300001347858us-gaap:CommonStockMember2026-01-012026-03-310001347858us-gaap:CommonStockMember2025-01-012025-03-310001347858us-gaap:SubsequentEventMember2026-11-052026-11-0500013478582026-11-052026-11-0500013478582026-06-122026-06-1200013478582026-01-262026-01-2600013478582025-06-202025-06-200001347858us-gaap:RetainedEarningsMember2026-09-300001347858us-gaap:AdditionalPaidInCapitalMember2026-09-300001347858us-gaap:RetainedEarningsMember2026-06-300001347858us-gaap:AdditionalPaidInCapitalMember2026-06-300001347858us-gaap:RetainedEarningsMember2026-03-310001347858us-gaap:AdditionalPaidInCapitalMember2026-03-310001347858us-gaap:RetainedEarningsMember2025-12-310001347858us-gaap:AdditionalPaidInCapitalMember2025-12-310001347858us-gaap:RetainedEarningsMember2025-09-300001347858us-gaap:AdditionalPaidInCapitalMember2025-09-300001347858us-gaap:RetainedEarningsMember2025-06-300001347858us-gaap:AdditionalPaidInCapitalMember2025-06-3000013478582025-06-300001347858us-gaap:RetainedEarningsMember2025-03-310001347858us-gaap:AdditionalPaidInCapitalMember2025-03-3100013478582025-03-310001347858us-gaap:RetainedEarningsMember2024-12-310001347858us-gaap:AdditionalPaidInCapitalMember2024-12-310001347858us-gaap:SeriesBPreferredStockMemberus-gaap:PreferredStockMember2026-09-300001347858us-gaap:CommonStockMember2026-09-300001347858us-gaap:SeriesBPreferredStockMemberus-gaap:PreferredStockMember2026-06-300001347858us-gaap:CommonStockMember2026-06-300001347858us-gaap:SeriesBPreferredStockMemberus-gaap:PreferredStockMember2026-03-310001347858us-gaap:CommonStockMember2026-03-310001347858us-gaap:SeriesBPreferredStockMemberus-gaap:PreferredStockMember2025-12-310001347858us-gaap:CommonStockMember2025-12-310001347858us-gaap:SeriesBPreferredStockMemberus-gaap:PreferredStockMember2025-09-300001347858us-gaap:CommonStockMember2025-09-300001347858us-gaap:SeriesBPreferredStockMemberus-gaap:PreferredStockMember2025-06-300001347858us-gaap:CommonStockMember2025-06-300001347858us-gaap:SeriesBPreferredStockMemberus-gaap:PreferredStockMember2025-03-310001347858us-gaap:CommonStockMember2025-03-310001347858us-gaap:SeriesBPreferredStockMemberus-gaap:PreferredStockMember2024-12-310001347858us-gaap:CommonStockMember2024-12-310001347858us-gaap:EmployeeStockOptionMember2026-01-012026-03-310001347858us-gaap:EmployeeStockOptionMember2025-01-012025-12-310001347858us-gaap:EmployeeStockOptionMember2026-06-300001347858us-gaap:EmployeeStockOptionMember2026-03-310001347858us-gaap:EmployeeStockOptionMember2025-12-310001347858us-gaap:EmployeeStockOptionMember2026-04-012026-06-300001347858us-gaap:EmployeeStockOptionMember2026-07-012026-09-300001347858us-gaap:RestrictedStockUnitsRSUMember2026-01-012026-03-310001347858us-gaap:RestrictedStockUnitsRSUMember2026-06-300001347858us-gaap:RestrictedStockUnitsRSUMember2026-03-310001347858us-gaap:RestrictedStockUnitsRSUMember2025-12-310001347858us-gaap:RestrictedStockUnitsRSUMember2026-04-012026-06-300001347858us-gaap:SubsequentEventMember2026-11-130001347858xxii:VlnMember2026-07-012026-09-300001347858xxii:OtherTobaccoProductsMember2026-07-012026-09-300001347858xxii:FilteredCigarsMember2026-07-012026-09-300001347858xxii:ContractManufacturingMember2026-07-012026-09-300001347858xxii:CigarettesMember2026-07-012026-09-300001347858xxii:VlnMember2026-01-012026-09-300001347858xxii:OtherTobaccoProductsMember2026-01-012026-09-300001347858xxii:FilteredCigarsMember2026-01-012026-09-300001347858xxii:ContractManufacturingMember2026-01-012026-09-300001347858xxii:CigarettesMember2026-01-012026-09-300001347858xxii:VlnMember2025-07-012025-09-300001347858xxii:FilteredCigarsMember2025-07-012025-09-300001347858xxii:ContractManufacturingMember2025-07-012025-09-300001347858xxii:CigarettesMember2025-07-012025-09-300001347858xxii:VlnMember2025-01-012025-09-300001347858xxii:OtherTobaccoProductsMember2025-01-012025-09-300001347858xxii:FilteredCigarsMember2025-01-012025-09-300001347858xxii:ContractManufacturingMember2025-01-012025-09-300001347858xxii:CigarettesMember2025-01-012025-09-300001347858xxii:June2026ExistingWarrantsMember2026-06-082026-06-080001347858xxii:April2025InducementWarrantsMember2025-04-292025-04-290001347858us-gaap:SeriesAPreferredStockMemberxxii:August2025SeriesaConvertiblePreferredStockOfferingMember2025-08-222025-08-220001347858xxii:August2025SeriesaConvertiblePreferredStockOfferingMember2025-08-222025-08-220001347858us-gaap:SubsequentEventMember2026-11-132026-11-130001347858xxii:GvbPromissoryNote2025Member2026-01-012026-09-300001347858us-gaap:SeriesBPreferredStockMemberus-gaap:SubsequentEventMember2026-11-130001347858us-gaap:SeriesBPreferredStockMember2026-09-300001347858us-gaap:SeriesBPreferredStockMember2025-12-310001347858us-gaap:SeriesBPreferredStockMember2026-06-300001347858us-gaap:SeriesBPreferredStockMember2026-03-310001347858us-gaap:SeriesBPreferredStockMemberxxii:March2026SeriesBConvertiblePreferredStockOfferingMember2026-03-200001347858xxii:GvbPromissoryNote2025Member2025-09-182025-09-180001347858xxii:AtMarketOfferingMember2025-11-042025-11-040001347858us-gaap:SeriesBPreferredStockMember2026-06-082026-06-080001347858us-gaap:SeriesBPreferredStockMember2026-01-012026-09-300001347858us-gaap:SeriesAPreferredStockMember2026-01-012026-09-300001347858us-gaap:SeriesBPreferredStockMemberus-gaap:SubsequentEventMember2026-11-132026-11-130001347858us-gaap:SeriesBPreferredStockMemberus-gaap:PreferredStockMember2026-07-012026-09-300001347858us-gaap:RetainedEarningsMember2026-07-012026-09-300001347858us-gaap:SeriesBPreferredStockMemberus-gaap:PreferredStockMember2026-04-012026-06-300001347858us-gaap:RetainedEarningsMember2026-04-012026-06-3000013478582026-04-012026-06-300001347858us-gaap:SeriesBPreferredStockMemberus-gaap:PreferredStockMember2026-01-012026-03-310001347858us-gaap:RetainedEarningsMember2026-01-012026-03-3100013478582026-01-012026-03-310001347858us-gaap:RetainedEarningsMember2025-07-012025-09-300001347858us-gaap:RetainedEarningsMember2025-04-012025-06-3000013478582025-04-012025-06-300001347858us-gaap:RetainedEarningsMember2025-01-012025-03-3100013478582025-01-012025-03-310001347858xxii:NotesAndLoansPayableMember2026-09-300001347858xxii:GrassValleyFireMember2026-09-300001347858xxii:GrassValleyFireMember2025-12-310001347858us-gaap:TrademarksAndTradeNamesMember2026-09-300001347858us-gaap:LicensingAgreementsMember2026-09-300001347858us-gaap:ContractualRightsMember2026-09-300001347858us-gaap:TrademarksAndTradeNamesMember2025-12-310001347858us-gaap:LicensingAgreementsMember2025-12-310001347858us-gaap:ContractualRightsMember2025-12-310001347858srt:ScenarioPreviouslyReportedMember2025-01-012025-09-300001347858srt:RevisionOfPriorPeriodReclassificationAdjustmentMember2025-01-012025-09-300001347858xxii:LicenseAgreementMember2026-07-012026-09-300001347858xxii:LicenseAgreementMember2026-01-012026-09-300001347858us-gaap:LicensingAgreementsMember2026-01-012026-09-300001347858us-gaap:PatentsMember2025-07-012025-09-300001347858us-gaap:PatentsMember2025-01-012025-12-3100013478582025-01-012025-12-310001347858us-gaap:PatentsMember2025-01-012025-09-300001347858us-gaap:LicensingAgreementsMember2026-07-012026-09-300001347858us-gaap:LicensingAgreementsMember2026-01-012026-09-300001347858us-gaap:LicensingAgreementsMember2026-09-300001347858us-gaap:PatentsMember2025-12-310001347858us-gaap:LicensingAgreementsMember2025-12-310001347858xxii:GvbPromissoryNote2023Member2024-06-240001347858xxii:GvbPromissoryNote2023Member2025-03-310001347858xxii:Omnia2024WarrantsMember2025-01-012025-09-300001347858us-gaap:EmployeeStockOptionMember2026-09-300001347858us-gaap:RestrictedStockUnitsRSUMember2026-09-300001347858us-gaap:RestrictedStockUnitsRSUMember2026-01-012026-09-300001347858us-gaap:EmployeeStockOptionMember2026-01-012026-09-300001347858us-gaap:SellingGeneralAndAdministrativeExpense2026-07-012026-09-300001347858us-gaap:SellingGeneralAndAdministrativeExpense2026-01-012026-09-300001347858us-gaap:SellingGeneralAndAdministrativeExpense2025-07-012025-09-300001347858us-gaap:SellingGeneralAndAdministrativeExpense2025-01-012025-09-300001347858us-gaap:PatentsMember2026-09-300001347858us-gaap:DiscontinuedOperationsHeldforsaleMember2026-07-012026-09-300001347858us-gaap:DiscontinuedOperationsHeldforsaleMember2026-01-012026-09-300001347858us-gaap:DiscontinuedOperationsHeldforsaleMember2025-07-012025-09-300001347858us-gaap:DiscontinuedOperationsHeldforsaleMember2025-01-012025-09-300001347858us-gaap:LoansPayableMember2026-04-012026-06-300001347858us-gaap:NotesPayableOtherPayablesMember2025-10-312025-10-310001347858us-gaap:LoansPayableMember2025-04-012025-06-300001347858us-gaap:LoansPayableMember2026-06-300001347858us-gaap:LoansPayableMember2025-06-300001347858xxii:GvbPromissoryNote2023Memberus-gaap:BorrowingsMember2024-06-242024-06-240001347858us-gaap:NotesPayableOtherPayablesMember2025-10-310001347858xxii:SingleReportableSegmentMember2026-07-012026-09-300001347858xxii:SingleReportableSegmentMember2026-01-012026-09-300001347858xxii:SingleReportableSegmentMember2025-07-012025-09-300001347858xxii:SingleReportableSegmentMember2025-01-012025-09-300001347858xxii:VariousMemberxxii:ManufacturingEquipmentAgreementMember2026-09-300001347858xxii:VariousMemberxxii:ConsultingAgreementMember2026-09-300001347858xxii:NorthCarolinaStateUniversityMemberxxii:TestingServicesAgreementMember2026-09-300001347858xxii:NorthCarolinaStateUniversityMemberxxii:LicenseAgreementMember2026-09-300001347858xxii:CustomerMemberus-gaap:RevenueFromContractWithCustomerMemberus-gaap:CustomerConcentrationRiskMember2026-07-012026-09-300001347858xxii:CustomerCMemberus-gaap:RevenueFromContractWithCustomerMemberus-gaap:CustomerConcentrationRiskMember2026-07-012026-09-300001347858xxii:CustomerBMemberus-gaap:RevenueFromContractWithCustomerMemberus-gaap:CustomerConcentrationRiskMember2026-07-012026-09-300001347858xxii:CustomerMemberus-gaap:RevenueFromContractWithCustomerMemberus-gaap:CustomerConcentrationRiskMember2026-01-012026-09-300001347858xxii:CustomerCMemberus-gaap:RevenueFromContractWithCustomerMemberus-gaap:CustomerConcentrationRiskMember2026-01-012026-09-300001347858xxii:CustomerBMemberus-gaap:RevenueFromContractWithCustomerMemberus-gaap:CustomerConcentrationRiskMember2026-01-012026-09-300001347858xxii:AllOtherCustomersMemberus-gaap:RevenueFromContractWithCustomerMemberus-gaap:CustomerConcentrationRiskMember2026-01-012026-09-300001347858xxii:CustomerMemberus-gaap:RevenueFromContractWithCustomerMemberus-gaap:CustomerConcentrationRiskMember2025-07-012025-09-300001347858xxii:CustomerCMemberus-gaap:RevenueFromContractWithCustomerMemberus-gaap:CustomerConcentrationRiskMember2025-07-012025-09-300001347858xxii:CustomerBMemberus-gaap:RevenueFromContractWithCustomerMemberus-gaap:CustomerConcentrationRiskMember2025-07-012025-09-300001347858xxii:AllOtherCustomersMemberus-gaap:RevenueFromContractWithCustomerMemberus-gaap:CustomerConcentrationRiskMember2025-07-012025-09-300001347858xxii:CustomerMemberus-gaap:RevenueFromContractWithCustomerMemberus-gaap:CustomerConcentrationRiskMember2025-01-012025-09-300001347858xxii:CustomerCMemberus-gaap:RevenueFromContractWithCustomerMemberus-gaap:CustomerConcentrationRiskMember2025-01-012025-09-300001347858xxii:CustomerBMemberus-gaap:RevenueFromContractWithCustomerMemberus-gaap:CustomerConcentrationRiskMember2025-01-012025-09-300001347858xxii:AllOtherCustomersMemberus-gaap:RevenueFromContractWithCustomerMemberus-gaap:CustomerConcentrationRiskMember2025-01-012025-09-3000013478582026-06-3000013478582026-03-310001347858xxii:April2025InducementWarrantsMember2025-04-290001347858xxii:June2026InducementWarrantsMember2026-08-130001347858xxii:June2026InducementWarrantsMember2026-06-080001347858xxii:June2026ExistingWarrantsMember2026-06-080001347858xxii:PlacementAgentWarrantsMemberxxii:March2026SeriesBConvertiblePreferredStockOfferingMember2026-03-200001347858xxii:March2026PreferredStockWarrantsMemberxxii:March2026SeriesBConvertiblePreferredStockOfferingMember2026-03-200001347858xxii:PlacementAgentWarrantsMemberus-gaap:SeriesAPreferredStockMemberxxii:August2025SeriesaConvertiblePreferredStockOfferingMember2025-08-220001347858us-gaap:SeriesAPreferredStockMemberxxii:August2025SeriesaConvertiblePreferredStockOfferingMember2025-08-2200013478582025-09-3000013478582024-12-310001347858us-gaap:RestrictedStockUnitsRSUMember2026-07-012026-09-300001347858us-gaap:OptionMember2026-07-012026-09-300001347858us-gaap:RestrictedStockUnitsRSUMember2026-01-012026-09-300001347858us-gaap:OptionMember2026-01-012026-09-300001347858us-gaap:WarrantMember2025-07-012025-09-300001347858us-gaap:RestrictedStockUnitsRSUMember2025-07-012025-09-300001347858us-gaap:OptionMember2025-07-012025-09-300001347858us-gaap:WarrantMember2025-01-012025-09-300001347858us-gaap:RestrictedStockUnitsRSUMember2025-01-012025-09-300001347858us-gaap:OptionMember2025-01-012025-09-300001347858us-gaap:SeriesBPreferredStockMember2026-04-012026-06-300001347858xxii:AtMarketOfferingMember2026-01-012026-03-310001347858us-gaap:SeriesBPreferredStockMember2026-01-012026-03-310001347858us-gaap:ResearchAndDevelopmentExpense2026-07-012026-09-300001347858us-gaap:CostOfRevenue2026-07-012026-09-300001347858us-gaap:ResearchAndDevelopmentExpense2026-01-012026-09-300001347858us-gaap:CostOfRevenue2026-01-012026-09-300001347858us-gaap:ResearchAndDevelopmentExpense2025-07-012025-09-300001347858us-gaap:CostOfRevenue2025-07-012025-09-3000013478582025-07-012025-09-300001347858us-gaap:ResearchAndDevelopmentExpense2025-01-012025-09-300001347858us-gaap:CostOfRevenue2025-01-012025-09-3000013478582025-01-012025-09-3000013478582026-09-3000013478582025-12-3100013478582026-07-012026-09-3000013478582026-11-1300013478582026-01-012026-09-30xbrli:sharesiso4217:USDiso4217:USDxbrli:sharesxbrli:purexxii:segmentxxii:installmentxxii:D

Table of Contents

​

​

UNITED STATES

SECURITIES AND EXCHANGE

COMMISSION WASHINGTON, D.C. 20549

​

FORM 10-Q

​

☒

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

​

For the Quarterly Period Ended September 30, 2026

​

☐

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

​

For the Transition Period From ________ to ________

​

Commission File Number: 001-36338​

22nd Century Group, Inc.

(Exact name of registrant as specified in its charter)

​

Nevada

  ​ ​ ​

98-0468420

(State or other jurisdiction

​

(IRS Employer

of incorporation)

​

Identification No.)

​

321 Farmington Road Mocksville, North Carolina 27028

(Address of principal executive offices)

​

(336) 940-3769

(Registrant’s telephone number, including area code)

​

Securities registered under Section 12(b) of the Act:

​

Title of each class

  ​ ​ ​

Ticker symbol

  ​ ​ ​

Name of Exchange on Which Registered

Common Stock, $0.00001 par value

 

XXII 

 

NASDAQ Capital Market

​

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

Yes  ⌧  No  ◻

​

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).

Yes  ⌧  No  ◻

​

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

​

Large accelerated filer

☐

Accelerated filer

☐

Non-accelerated filer

☒

Smaller reporting company

☒

 

Emerging growth company

☐

​

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ◻

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

Yes  ☐ No  ☒

​

As of November 13, 2026, there were 3,210,207 shares of common stock issued and outstanding.

​

​

​

​

Table of Contents

22nd CENTURY GROUP, INC.

​

INDEX

​

​

​

 

 

Page

Number

PART I.

FINANCIAL INFORMATION

 

 

 

 

Item 1.

Financial Statements

 

 

 

 

​

Condensed Consolidated Balance Sheets as of September 30, 2026 and December 31, 2025 (unaudited)

3

​

 

 

​

Condensed Consolidated Statements of Operations and Comprehensive Income (Loss) for the Three and Nine

Months ended September 30, 2026 and 2025 (unaudited)

4

​

 

 

​

Condensed Consolidated Statements of Convertible Preferred Stock, Shareholders’ Equity and Mezzanine Equity for the Three and Nine Months ended September 30, 2026 and 2025 (unaudited)

5

​

 

 

​

Condensed Consolidated Statements of Cash Flows for the Nine Months ended September 30, 2026 and 2025 (unaudited)

7

​

 

 

​

Notes to Condensed Consolidated Financial Statements (unaudited)

8

​

 

 

Item 2.

Management’s Discussion and Analysis of Financial Condition and Results of Operations

28

​

​

​

Item 3.

Quantitative and Qualitative Disclosures about Market Risk

36

 

 

 

Item 4.

Controls and Procedures

36

 

 

 

PART II.

OTHER INFORMATION

38

 

 

 

Item 1.

Legal Proceedings

38

 

 

 

Item 1A.

Risk Factors

38

 

 

 

Item 2.

Unregistered Sales of Equity Securities and Use of Proceeds

39

 

 

 

Item 3.

Default Upon Senior Securities

39

 

 

 

Item 4.

Mine Safety Disclosures

39

 

 

 

Item 5.

Other Information

39

 

 

 

Item 6.

Exhibits

40

 

 

 

SIGNATURES

41

​

​

​

​

​

2

Table of Contents

22nd CENTURY GROUP, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

(Unaudited)

(amounts in thousands, except share and per-share data)

​

​

​

​

​

​

​

​

​

​

September 30, 

​

December 31, 

​

  ​ ​ ​

2026

  ​ ​ ​

2025

ASSETS

 

​

  ​

 

​

  ​

Current assets:

 

​

  ​

 

​

  ​

Cash and cash equivalents

​

$

3,911

​

$

7,149

Accounts receivable, net

​

 

4,109

​

 

3,594

Inventories

​

 

4,357

​

 

4,326

Prepaid expenses and other current assets

​

 

1,887

​

 

2,562

Total current assets

​

 

14,264

​

 

17,631

Property, plant and equipment, net

​

 

2,808

​

 

2,440

Operating lease right-of-use assets, net

​

 

605

​

 

728

Intangible assets, net

​

 

5,638

​

 

6,224

Other assets

​

 

42

​

 

—

Total assets

​

$

23,357

​

$

27,023

​

​

 

  ​

​

 

  ​

LIABILITIES, MEZZANINE EQUITY AND SHAREHOLDERS' EQUITY

​

 

  ​

​

 

  ​

Current liabilities:

​

 

  ​

​

 

  ​

Notes and loans payable-current

​

$

405

​

$

204

Operating lease obligations

​

 

180

​

 

168

Accounts payable

​

 

821

​

 

1,000

Accrued expenses and other current liabilities

​

 

789

​

 

836

Accrued excise taxes and fees

​

 

3,058

​

 

3,343

Contract liabilities

​

 

1,037

​

 

1,721

Total current liabilities

​

 

6,290

​

 

7,272

Long-term liabilities:

​

 

  ​

​

 

  ​

Notes and loans payable

​

 

416

​

 

504

Operating lease obligations

​

 

464

​

 

601

Other long-term liabilities

​

​

111

​

​

154

Total liabilities

​

​

7,281

​

​

8,531

Commitments and contingencies (Note 12)

​

 

​

​

 

​

​

​

​

​

​

​

​

Mezzanine equity:

​

​

​

​

​

​

Series A convertible preferred shares, $0.00001 par value; 10,000,000 shares authorized, 0 shares issued and outstanding at September 30, 2026 and 9,650 at December 31, 2025, respectively

​

 

—

​

 

2,734

Total mezzanine equity

​

 

—

​

 

2,734

​

​

​

​

​

​

​

Shareholders' equity:

​

 

  ​

​

 

  ​

Series B convertible preferred shares, $0.00001 par value; 10,000,000 shares authorized, 8,505 shares issued and outstanding at September 30, 2026 and 0 at December 31, 2025, respectively

​

​

—

​

​

—

Common stock, $.00001 par value, 500,000,000 shares authorized, 20,032 shares issued and outstanding at September 30, 2026 and 391 at December 31, 2025, respectively

​

 

—

​

 

—

Capital in excess of par value

​

 

424,401

​

 

414,683

Accumulated deficit

​

 

(408,325)

​

 

(398,925)

Total shareholders' equity

​

 

16,076

​

 

15,758

Total liabilities, mezzanine equity and shareholders’ equity

​

$

23,357

​

$

27,023

​

See accompanying notes to Condensed Consolidated Financial Statements.

​

​

​

3

Table of Contents

22nd CENTURY GROUP, INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS)

(Unaudited)

(amounts in thousands, except share and per-share data)

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

Three Months Ended

​

Nine Months Ended

​

​

September 30, 

​

September 30, 

​

  ​ ​ ​

2026

  ​ ​ ​

2025

  ​ ​ ​

2026

  ​ ​ ​

2025

Revenues, net

​

$

4,759

​

$

4,011

​

$

11,729

​

$

14,050

Cost of goods sold

​

​

1,655

​

 

2,557

​

​

5,201

​

​

8,304

Excise taxes and fees on products

​

 

2,658

​

 

2,513

​

 

7,009

​

 

8,049

Gross profit (loss)

​

 

446

​

 

(1,059)

​

 

(481)

​

 

(2,303)

Operating expenses:

​

 

  ​

​

 

  ​

​

 

​

​

 

​

Sales, general and administrative

​

 

2,451

​

 

1,849

​

 

7,272

​

 

5,766

Research and development

​

 

233

​

 

193

​

 

813

​

 

583

Other operating expense, net

​

​

339

​

 

111

​

 

339

​

 

111

Total operating expenses

​

 

3,023

​

 

2,153

​

 

8,424

​

 

6,460

Operating loss from continuing operations

​

 

(2,577)

​

 

(3,212)

​

 

(8,905)

​

 

(8,763)

Other (income) expense:

​

 

  ​

​

 

  ​

​

 

​

​

 

​

Other expense

​

 

—

​

 

33

​

 

—

​

 

207

Interest income

​

 

(30)

​

 

(16)

​

 

(104)

​

 

(46)

Interest expense

​

 

17

​

 

534

​

 

47

​

 

1,443

Total other (income) expense, net

​

 

(13)

​

 

551

​

 

(57)

​

 

1,604

Loss from continuing operations before income taxes

​

 

(2,564)

​

​

(3,763)

​

 

(8,848)

​

​

(10,367)

(Benefit) provision for income taxes

​

 

—

​

​

—

​

 

—

​

 

(34)

Net loss from continuing operations

​

$

(2,564)

​

$

(3,763)

​

$

(8,848)

​

$

(10,333)

​

​

​

​

​

​

​

​

​

​

​

​

​

Discontinued operations:

​

​

​

​

​

​

​

​

​

​

​

​

(Loss) income from discontinued operations before income taxes

​

$

(229)

​

$

9,252

​

$

(552)

​

$

8,087

Provision for income taxes

​

​

—

​

​

—

​

​

—

​

​

—

Net (loss) income from discontinued operations

​

$

(229)

​

$

9,252

​

$

(552)

​

$

8,087

​

​

​

​

​

​

​

​

​

​

​

​

​

Net (loss) income

​

$

(2,793)

​

$

5,489

​

$

(9,400)

​

$

(2,246)

Comprehensive (loss) income

​

$

(2,793)

​

$

5,489

​

$

(9,400)

​

$

(2,246)

​

​

​

​

​

​

​

​

​

​

​

​

​

Net (loss) income

​

$

(2,793)

​

$

5,489

​

$

(9,400)

​

$

(2,246)

Deemed dividends

​

​

—

​

​

—

​

​

(18,134)

​

​

—

Dividend for redemption of Series A Convertible Preferred Stock

​

​

—

​

​

—

​

​

(6,916)

​

​

—

Dividend for redemption of Series B Convertible Preferred Stock

​

​

—

​

​

—

​

​

(870)

​

​

—

Net (loss) income available to common shareholders

​

$

(2,793)

​

$

5,489

​

$

(35,320)

​

$

(2,246)

​

​

​

​

​

​

​

​

​

​

​

​

​

Basic and diluted loss per share:

​

​

​

​

​

​

​

​

​

​

​

​

Basic and diluted loss per common share from continuing operations

​

$

(227.49)

​

$

(19,701.57)

​

$

(1,719.39)

​

$

(147,614.29)

Basic and diluted (loss) income per common share from discontinued operations

​

$

(20.32)

​

$

48,439.79

​

$

(107.27)

​

$

115,528.57

Basic and diluted (loss) income available to common shareholders per common share

​

$

(247.80)

​

$

28,738.22

​

$

(6,863.58)

​

$

(32,085.71)

​

​

​

​

​

​

​

​

​

​

​

​

​

Weighted average shares outstanding - basic and diluted

​

​

11,271

​

​

191

​

​

5,146

​

​

70

​

​

​

​

​

​

​

​

​

​

​

​

​

​

See accompanying notes to Condensed Consolidated Financial Statements.

​

4

Table of Contents

​

22nd CENTURY GROUP, INC.

CONDENSED CONSOLIDATED STATEMENTS OF CONVERTIBLE PREFERRED STOCK, SHAREHOLDERS’ EQUITY AND

MEZZANINE EQUITY

(Unaudited)

(amounts in thousands, except share data)

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

Nine Months Ended September 30, 2026

​

​

Shareholders' Equity

​

​

Mezzanine Equity

​

​

Convertible

​

​

​

​

​

​

​

​

​

Capital in

​

​

​

​

Total

​

​

Preferred

​

​

 

​

​

Preferred Shares

​

​

​

​

Common Shares

​

​

​

​

Excess of

​

Accumulated

​

Shareholders’

​

​

Shares

​

​

 

​

  ​ ​ ​

Outstanding

  ​ ​ ​

Par Value

  ​ ​ ​

Outstanding*

  ​ ​ ​

Par Value

  ​ ​ ​

Par Value*

  ​ ​ ​

Deficit

  ​ ​ ​

Equity

​

​

Outstanding

​

Amount

Balance at January 1, 2026

 

—

​

$

—

 

391

​

$

—

 

$

414,683

​

$

(398,925)

​

$

15,758

​

​

9,650

​

$

2,734

Stock issued in connection with ATM, net of fees of $136

​

—

​

​

—

​

42

​

​

—

​

​

64

​

​

—

​

​

64

​

​

—

​

​

—

Reclassification of 9,650 shares of Mezzanine Equity Series A Convertible Preferred Stock

​

9,650

​

​

—

​

—

​

​

—

​

​

2,734

​

​

—

​

​

2,734

​

​

(9,650)

​

​

(2,734)

Redemption of Series A Convertible Preferred Stock (see Note 10)

​

(9,650)

​

​

—

​

—

​

​

—

​

​

(9,650)

​

​

—

​

​

(9,650)

​

​

—

​

​

—

Issuance of Series B Convertible Preferred Stock, net of fees of $725

​

16,000

​

​

—

​

—

​

​

—

​

​

15,275

​

​

—

​

​

15,275

​

​

—

​

​

—

Stock issued upon conversion of Series B convertible preferred stock

​

(230)

​

​

—

​

85

​

​

—

​

​

—

​

​

—

​

​

—

​

​

—

​

​

—

Stock issued in connection with RSU vesting

​

—

​

​

—

​

1

​

​

—

​

​

—

​

​

—

​

​

—

​

​

—

​

​

—

Equity-based compensation

 

—

​

​

—

 

15

​

 

—

 

​

298

​

​

—

​

 

298

​

​

—

​

 

—

Fractional shares issued for reverse stock split

 

—

​

​

—

 

93

​

 

—

 

​

—

​

​

—

​

 

—

​

​

—

​

 

—

Net loss

 

—

​

​

—

 

—

​

 

—

 

​

—

​

​

(3,261)

​

 

(3,261)

​

​

—

​

 

—

Balance at March 31, 2026

​

15,770

​

$

—

 

627

​

$

—

 

$

423,404

​

$

(402,186)

​

$

21,218

​

​

—

​

$

—

Issuance of Series B Convertible Preferred Stock, net of fees of $1

​

25

​

​

—

​

—

​

​

—

​

​

24

​

​

—

​

​

24

​

​

—

​

​

—

Stock issued upon conversion of Series B convertible preferred stock

​

(5,280)

​

​

—

​

3,527

​

​

—

​

​

—

​

​

—

​

​

—

​

​

—

​

​

—

Stock issued in connection with warrant exercises, net of fees of $164

​

—

​

​

—

​

2,952

​

​

—

​

​

2,309

​

​

—

​

​

2,309

​

​

—

​

​

—

Redemption of Series B Convertible Preferred Stock (see Note 10)

​

(2,010)

​

​

—

​

—

​

​

—

​

​

(2,010)

​

​

—

​

​

(2,010)

​

​

—

​

​

—

Stock issued from alternative cashless warrant exercises

​

—

​

​

—

​

122

​

​

—

​

​

—

​

​

—

​

​

—

​

​

—

​

​

—

Equity-based compensation

​

—

​

​

—

​

1,036

​

​

—

​

​

446

​

​

—

​

​

446

​

​

—

​

​

—

Fractional shares issued for reverse stock split

​

—

​

​

—

​

1,682

​

​

—

​

​

—

​

​

—

​

​

—

​

​

—

​

​

—

Net loss

​

—

​

​

—

​

—

​

​

—

​

​

—

​

​

(3,346)

​

​

(3,346)

​

​

—

​

​

—

Shares held in abeyance

​

—

​

​

—

​

(1,295)

​

​

—

​

​

—

​

​

—

​

​

—

​

​

—

​

​

—

Balance at June 30, 2026

 

8,505

​

$

—

​

8,651

​

$

—

​

$

424,173

​

$

(405,532)

​

$

18,641

​

​

—

​

$

—

Stock issued from abeyance

​

—

​

​

—

​

2,963

​

​

—

​

​

—

​

​

—

​

​

—

​

​

—

​

​

—

Stock issued from alternative cashless warrant exercises, net

​

—

​

​

—

​

47,288

​

​

—

​

​

—

​

​

—

​

​

—

​

​

—

​

​

—

Equity-based compensation

​

—

​

​

—

​

—

​

​

—

​

​

228

​

​

—

​

​

228

​

​

—

​

​

—

Net loss

​

—

​

​

—

​

—

​

​

—

​

​

—

​

​

(2,793)

​

​

(2,793)

​

​

—

​

​

—

Shares held in abeyance

​

—

​

​

—

​

(38,870)

​

​

—

​

​

—

​

​

—

​

​

—

​

​

—

​

​

—

Balance at September 30, 2026

 

8,505

​

$

—

​

20,032

​

$

—

​

$

424,401

​

$

(408,325)

​

$

16,076

​

​

—

​

$

—

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

*Giving retroactive effect to the 1-for-15 reverse stock splits on January 26, 2026, 1-for-20 on June 12, 2026 and 1-for-58 on November 5, 2026.

​

5

Table of Contents

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

Nine Months Ended September 30, 2025

​

​

Shareholders' Equity

​

​

Mezzanine Equity

​

​

Convertible

​

​

​

​

​

​

​

​

​

Capital in

​

​

​

​

Total

​

​

Preferred

​

​

 

​

​

Preferred Shares

​

​

​

​

Common Shares

​

​

​

​

Excess of

​

Accumulated

​

Shareholders’

​

​

Shares

​

​

 

​

  ​ ​ ​

Outstanding

  ​ ​ ​

Par Value

  ​ ​ ​

Outstanding*

  ​ ​ ​

Par Value

  ​ ​ ​

Par Value*

  ​ ​ ​

Deficit

  ​ ​ ​

Equity

​

​

Outstanding

​

Amount

Balance at January 1, 2025

 

—

​

$

—

 

1

​

$

—

 

$

397,883

 

$

(393,871)

​

$

4,012

​

​

—

​

$

—

Stock issued in connection with settled indebtedness

​

—

​

​

—

​

1

​

​

—

​

​

270

​

​

—

​

​

270

​

​

—

​

​

—

Stock issued in connection with licensing arrangement

​

—

​

​

—

​

1

​

​

—

​

​

230

​

​

—

​

​

230

​

​

—

​

​

—

Stock issued from alternative cashless warrant exercises

​

—

​

​

—

​

1

​

​

—

​

​

—

​

​

—

​

​

—

​

​

—

​

​

—

Stock issued upon conversion of Senior Secured Credit Facility

​

—

​

​

—

​

3

​

​

—

​

​

3,132

​

​

—

​

​

3,132

​

​

—

​

​

—

Conversion option remeasurement

​

—

​

​

—

​

—

​

​

—

​

​

283

​

​

—

​

​

283

​

​

—

​

​

—

Equity-based compensation

 

—

​

 

—

 

—

​

 

—

 

​

26

 

​

—

​

 

26

​

​

—

​

 

—

Net loss

 

—

​

 

—

 

—

​

 

—

 

​

—

 

​

(4,328)

​

 

(4,328)

​

​

—

​

 

—

Balance at March 31, 2025

​

—

​

$

—

 

7

​

$

—

 

$

401,824

 

$

(398,199)

​

$

3,625

​

​

—

​

$

—

Stock issued in connection with warrant exercises, net of fees of $363

​

—

​

​

—

​

21

​

​

—

​

​

5,075

​

​

—

​

​

5,075

​

​

—

​

​

—

Stock issued from alternative cashless warrant exercises

​

—

​

​

—

​

1

​

​

—

​

​

—

​

​

—

​

​

—

​

​

—

​

​

—

Stock issued in connection with settled indebtedness

​

—

​

​

—

​

1

​

​

—

​

​

230

​

​

—

​

​

230

​

​

—

​

​

—

Equity-based compensation

​

—

​

​

—

​

—

​

​

—

​

​

107

​

​

—

​

​

107

​

​

—

​

​

—

Fractional shares issued for reverse stock split

​

—

​

​

—

​

7

​

​

—

​

​

—

​

​

—

​

​

—

​

​

—

​

​

—

Net loss

​

—

​

​

—

​

—

​

​

—

​

​

—

​

​

(3,407)

​

​

(3,407)

​

​

—

​

​

—

Shares held in abeyance

​

—

​

​

—

​

(11)

​

​

—

​

​

—

​

​

—

​

​

—

​

​

—

​

​

—

Balance at June 30, 2025

​

—

​

$

—

​

26

​

$

—

​

$

407,236

​

$

(401,606)

​

$

5,630

​

​

—

​

$

—

Shares issued from abeyance

​

—

​

​

—

​

11

​

​

—

​

​

—

​

​

—

​

​

—

​

​

—

​

​

—

Stock issued from alternative cashless warrant exercises

​

—

​

​

—

​

286

​

​

—

​

​

—

​

​

—

​

​

—

​

​

—

​

​

—

Stock issued in connection with the issuance of Series A Convertible Preferred Stock, net of fees of $757

​

—

​

​

—

​

—

​

​

—

​

​

6,876

​

​

—

​

​

6,876

​

​

10,650

​

​

3,017

Stock issued upon conversion of preferred stock

​

—

​

​

—

​

27

​

​

—

​

​

283

​

​

—

​

​

283

​

​

(1,000)

​

​

(283)

Equity-based compensation

​

—

​

​

—

​

—

​

​

—

​

​

92

​

​

—

​

​

92

​

​

—

​

​

—

Fractional shares issued for reverse stock split

​

—

​

​

—

​

1

​

​

—

​

​

—

​

​

—

​

​

—

​

​

—

​

​

—

Net loss

​

—

​

​

—

​

—

​

​

—

​

​

—

​

​

5,489

​

​

5,489

​

​

—

​

​

—

Balance at September 30, 2025

 

—

​

$

—

​

351

​

$

—

​

$

414,487

​

$

(396,117)

​

$

18,370

​

​

9,650

​

$

2,734

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

*Giving retroactive effect to the 1-for-23 reverse stock split on June 20, 2025, 1-for-15 on January 26, 2026, 1-for-20 on June 12, 2026 and 1-for-58 on November 5, 2026.

​

See accompanying notes to Condensed Consolidated Financial Statements.

6

Table of Contents

22nd CENTURY GROUP, INC.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(Unaudited)

(amounts in thousands)

​

​

​

​

​

​

​

​

​

Nine Months Ended

​

​

September 30, 

​

  ​ ​ ​

2026

  ​ ​ ​

2025

Cash flows from operating activities:

 

​

  ​

 

​

  ​

Net loss

​

$

(9,400)

​

$

(2,246)

Adjustments to reconcile net loss to cash used in operating activities:

​

 

  ​

​

 

  ​

Impairment of long-lived assets - held for sale

​

​

—

​

​

293

Impairment of long-lived assets

​

​

339

​

​

111

Amortization and depreciation

​

 

623

​

 

694

Amortization of right-of-use assets

​

 

123

​

 

206

Other non-cash gains

​

​

—

​

​

(32)

Provision for credit losses

​

​

(23)

​

​

507

(Gain) loss on sale or disposal of property, plant, and equipment

​

 

—

​

 

(12)

Debt related charges included in interest expense

​

​

—

​

​

1,586

Equity-based compensation

​

 

885

​

 

225

Change in fair value of warrant liabilities

​

​

—

​

​

207

Change in inventory reserves

​

​

224

​

​

(215)

Changes in operating assets and liabilities:

​

 

  ​

​

 

​

Accounts receivable

​

 

(517)

​

 

(1,301)

Inventories

​

 

(255)

​

 

(676)

Prepaid expenses and other assets

​

 

774

​

 

(1,610)

Insurance recoveries

​

 

—

​

 

(9,500)

Accounts payable

​

 

(186)

​

 

(672)

Accrued expenses and other current liabilities

​

 

(58)

​

 

834

Accrued excise taxes and fees

​

 

(285)

​

 

1,361

Contract liabilities

​

 

(684)

​

 

59

Other liabilities

​

​

(196)

​

 

(291)

Net cash used in operating activities

​

 

(8,636)

​

 

(10,472)

Cash flows from investing activities:

​

 

  ​

​

 

​

Acquisition of patents, trademarks, and licenses

​

 

(28)

​

 

(75)

Acquisition of property, plant and equipment

​

 

(712)

​

 

(45)

Proceeds from the sale of property, plant and equipment

​

 

—

​

 

770

Issuance of 2025 GVB promissory note

​

 

—

​

 

(500)

Payments received from 2025 GVB promissory note

​

​

25

​

​

—

Net cash (used in) provided by investing activities

​

 

(715)

​

 

150

Cash flows from financing activities:

​

 

  ​

​

 

​

Payments on notes payable

​

​

(689)

​

​

(909)

Proceeds from issuance of common stock related to the ATM

​

​

200

​

​

—

Payment of common stock issuance costs related to the ATM

​

​

(136)

​

​

—

Proceeds from issuance of notes payable

​

​

802

​

​

1,023

Payments of penalties from long-term debt

​

​

—

​

​

(28)

Payments of long-term debt

​

​

—

​

​

(4,308)

Net proceeds from warrant exercise

​

​

2,309

​

​

5,075

Net proceeds from Series A convertible preferred stock

​

​

—

​

​

9,893

Principal payments on finance leases

​

​

(12)

​

​

—

Redemption of Series A at par value

​

​

(9,650)

​

​

—

Redemption of Series B at par value

​

​

(2,010)

​

​

—

Net proceeds from Series B convertible preferred stock

​

​

15,299

​

​

—

Net cash provided by financing activities

​

 

6,113

​

 

10,746

Net (decrease) increase in cash and cash equivalents

​

 

(3,238)

​

 

424

Cash and cash equivalents - beginning of period

​

 

7,149

​

 

4,422

Cash and cash equivalents - end of period

​

$

3,911

​

$

4,846

​

​

​

​

​

​

​

Supplemental disclosures of cash flow information:

​

 

  ​

​

 

  ​

Non-cash transactions:

​

 

  ​

​

 

  ​

Capital expenditures incurred but not yet paid

​

$

5

​

$

621

Deemed dividends

​

$

18,134

​

$

—

Stock issued in connection with settled indebtedness

​

$

—

​

$

500

Non-cash licensing arrangement

​

$

—

​

$

230

Right-of-use assets and corresponding operating lease obligations

​

$

—

​

$

(666)

Insurance recoveries release

​

$

—

​

$

768

Payment of 2023 GVB promissory note

​

$

—

​

$

500

Equity conversion of Senior Secured Credit Facility

​

$

—

​

$

3,132

Conversion option remeasurement

​

$

—

​

$

283

Finance lease assets and lease obligations

​

$

52

​

$

—

​

​

See accompanying notes to Condensed Consolidated Financial Statements.

​

7

Table of Contents

​

22nd CENTURY GROUP, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

September 30, 2026

(Unaudited)

Amounts in thousands, except for share and per-share data

NOTE 1. - NATURE OF BUSINESS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Basis of Presentation – 22nd Century Group, Inc. (together with its consolidated subsidiaries, “22nd Century Group” or the “Company”) is a Nevada corporation publicly traded on the NASDAQ Capital Market under the symbol “XXII.” 22nd Century Group is a tobacco products company with sales and distribution of the Company’s own branded tobacco products and contract manufacturing services for third-party brands. The Company’s flagship product is a reduced nicotine combustible cigarette authorized by the FDA as a Modified Risk Tobacco Product.

The accompanying Condensed Consolidated Financial Statements are presented in accordance with the rules and regulations of the United States ("U.S.") Securities and Exchange Commission ("SEC") and do not include all of the disclosures required by U.S. generally accepted accounting principles (“U.S. GAAP”) as contained in the Company’s Annual Report on Form 10-K. Accordingly, these Condensed Consolidated Financial Statements should be read in conjunction with the Consolidated Financial Statements and notes thereto included in the Company’s most recent Annual Report on Form 10-K for the fiscal year ended December 31, 2025.

In the opinion of management, the Condensed Consolidated Financial Statements reflect all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation of the results of the Company for the periods presented. The results for interim periods are not necessarily indicative of results or trends that may be expected for the entire fiscal year. The Condensed Consolidated Financial Statements were prepared using U.S. GAAP, which require management to make estimates and assumptions that affect the reported amounts of assets, liabilities, certain components of equity, sales, expenses, and related disclosures at the date of the financial statements and during the reporting period. Actual results could differ materially from these estimates.

Liquidity and Capital Resources – The Condensed Consolidated Financial Statements have been prepared in accordance with generally accepted accounting principles applicable to a going concern, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business.

The Company has incurred significant losses and negative cash flows from operations since inception and expects to incur additional losses until such time that it can generate significant revenue and profit in its tobacco business. The Company had negative cash flow from operations of $8,636 and $10,472 for the nine months ended September 30, 2026 and 2025, respectively, and an accumulated deficit of $408,325 and $398,925 as of September 30, 2026 and December 31, 2025, respectively. As of September 30, 2026, the Company had cash and cash equivalents of $3,911.

Given the Company’s projected operating requirements and its existing cash and cash equivalents, there is substantial doubt about the Company’s ability to continue as a going concern through one year following the date that the Condensed Consolidated Financial Statements are issued.

In response to these conditions, management continues to evaluate different strategies for reducing expenses, as well as pursuing financing strategies which include raising additional funds through the issuance of debt or equity securities, asset sales, and through arrangements with strategic partners. If capital is not available to the Company when, and in the amounts needed, it could be required to liquidate inventory, cease or curtail operations, or seek protection under applicable bankruptcy laws or similar state proceedings. There can be no assurance that the Company will be able to raise the capital it needs to continue operations. Management’s plans do not alleviate substantial doubt about the Company’s ability to continue as a going concern through one year following the date that the Condensed Consolidated Financial Statements are issued.

The Condensed Consolidated Financial Statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might result from the outcome of this uncertainty.

8

Table of Contents

Other Significant Risks and Uncertainties - The Company is subject to a number of risks, including, but not limited to, the lack of available capital; ability to remain listed on Nasdaq; unsuccessful commercialization strategy and launch plans for the Company’s products or market acceptance of the Company’s products; and protection of proprietary technology.

Reclassifications – The Company has revised the presentation and classification of the following in the Condensed Consolidated Statements of Cash Flows as follows:

​

​

​

​

​

​

​

​

​

​

​

Nine Months Ended

​

September 30, 2025

​

As originally

​

​

​

​

​

​

​

reported

  ​ ​ ​

Reclass

  ​ ​ ​

Revised

Accrued expenses and other current liabilities

$

1,012

​

$

(178)

​

$

834

Accrued payroll

$

(178)

​

$

178

​

$

—

Contract liabilities

$

—

​

$

59

​

$

59

Other liabilities

$

(232)

​

$

(59)

​

$

(291)

​

Reverse Stock Split – In order to regain compliance with Nasdaq's continued listing requirements, the Company effected the following reverse stock splits:

​

​

​

​

​

​

​

​

​

​

Round up of

Date

​

Split

​

fractional shares

June 20, 2025

​

1-for-23

​

7

January 26, 2026

​

1-for-15

​

93

June 12, 2026

​

1-for-20

​

1,682

November 5, 2026

​

1-for-58

​

Pending final determination

​

The number of additional shares issued as a result of rounding fractional shares in connection with the November 5, 2026 reverse stock split has not yet been finalized.

All share and per share amounts, and exercise prices of stock options, and warrants in the Condensed Consolidated Financial Statements and notes thereto have been retroactively adjusted for all periods presented to give effect to the reverse stock splits.

Mezzanine Equity - Where common or preferred shares are determined to be conditionally redeemable upon the occurrence of certain events that are not solely within the control of the Company, and upon such event, the shares would become redeemable at the option of the holder, such as when the Company has not obtained shareholder approval for certain provisions of the outstanding preferred shares, they are classified as "mezzanine equity" (temporary equity). The purpose of this classification is to convey that such a security may not be permanently part of equity and could result in a demand for cash, securities or other assets of the entity in the future. The Company evaluates whether the contingent redemption provisions are probable of becoming redeemable to determine whether the carrying value of the redeemable convertible preferred shares are required to be remeasured to their respective redemption values. All instruments that are classified as mezzanine equity are evaluated for embedded derivative features by evaluating each feature against the nature of the host instrument (e.g., more equity-like or debt-like). Features identified as freestanding instruments or bifurcated embedded derivatives that are material are recognized separately as a derivative asset or liability in the Condensed Consolidated Financial Statements.

Warrants - The Company accounts for stock warrants as either equity instruments, derivative liabilities, or liabilities in accordance with ASC 480, Distinguishing Liabilities from Equity (“ASC 480”) and ASC 815, Derivatives and Hedging (“ASC 815”) depending on the specific terms of the warrant agreement. The assessment considers whether the warrants are freestanding financial instruments pursuant to ASC 480, meet the definition of a liability pursuant to ASC 480, and whether the warrants meet all of the requirements for equity classification under ASC 815, including whether the warrants are indexed to the Company’s common stock and whether the warrant holders could potentially require “net cash settlement” in a circumstance outside of the Company’s control, among other conditions for equity classification. This assessment, which requires the use of professional judgment, is conducted at the time of warrant issuance and as of each subsequent quarterly period end date while the warrants are outstanding. 

9

Table of Contents

Warrants that the Company may be required to redeem through payment of cash or other assets outside its control are classified as liabilities pursuant to ASC 480 and are initially and subsequently measured at their estimated fair values. For issued or modified warrants that meet all of the criteria for equity classification, the warrants are required to be recorded as a component of Capital in excess of par value at the time of issuance. For additional discussion on warrants, see Note 5 “Fair Value Measurements” and Note 10 “Capital Raises and Warrants for Common Stock.”

Deemed dividends associated with down round provisions (commonly referred to as “ratchets”) represent the economic transfer of value to holders of equity-classified freestanding financial instruments when these provisions are triggered. These deemed dividends are presented as a reduction in net income or an increase in net loss available to common shareholders and a corresponding increase to Capital in excess of par value resulting in no change to stockholders’ equity/deficit. See Note 10 “Capital Raises and Warrants for Common Stock.”

Offering Costs - In connection with equity offerings, the Company incurs and capitalizes certain direct, incremental legal, professional, accounting and other third-party costs. Such costs are offset against the gross proceeds of each equity offering and recorded as a component of Capital in excess of par in the Condensed Consolidated Balance Sheets upon the consummation of the offering. Additionally, the Company also applies the guidance in ASC 815-40-55-50 in connection with an offering, such as an inducement of outstanding warrants, whereby if the modification or exchange of a free-standing equity classified written call option increases the fair value, the Company records the incremental fair value as an equity issuance cost. See Note 10 “Capital Raises and Warrant For Common Stock” for further discussion of net proceeds associated with equity offerings.

Impairment of Long-Lived Assets - The Company reviews all long-lived assets to be held and used for recoverability, when events or changes in circumstances occur that indicate that the carrying value of the asset may not be recoverable. The assessment of possible impairment is based on the ability to recover the carrying value of the assets from the expected future cash flows (undiscounted and without interest expense) of the related operations. If these cash flows are less than the carrying value of such assets, an impairment loss for the difference between the estimated fair value and carrying value is recorded.

On July 1, 2026, the Company received termination notice from Smoker Friendly International, LLC (“SF”) with respect to its Master Service Agreement with the Company dated January 1, 2025. As a result, the Company determined an impairment triggering event occurred and recorded impairment charges for its related predicate licenses for SF tobacco products of $339 during the three and nine months ended September 30, 2026. The Company recorded impairment charge of $111 related to patents during the three and nine months ended September 30, 2025. Refer to Note 4 “Intangible Assets, Net.”

Revenue Recognition – The Company recognizes revenue when it satisfies a performance obligation by transferring control of the product to a customer. For additional discussion on revenue recognition, refer to Note 8 “Revenue Recognition”.

Income Taxes - For interim income tax reporting, due to a full valuation allowance on net deferred tax assets, no income tax expense or benefit is recorded unless it is related to certain state, local, or franchise taxes, or unusual or infrequently occurring items. The tax effects of unusual or infrequently occurring items, including changes in judgment about valuation allowances and effects of changes in tax laws or rates, are reported in the interim period in which they occur.

The Company and its subsidiaries file a consolidated U.S. federal income tax return. State tax returns are filed on a combined or separate basis depending on the applicable laws in the jurisdictions where the tax returns are filed.

Recently Issued Accounting Pronouncements

In November 2024, the FASB issued ASU 2024-03, Income Statement—Reporting Comprehensive Income—Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses. The ASU is intended to improve disclosures about a public business entity’s expense and provide more detailed information to investors about the types of expenses in commonly presented expense captions. The ASU is effective for fiscal years beginning after December 15, 2026, and interim periods within fiscal years beginning after December 15, 2027, with early adoption permitted. The Company is currently evaluating the impact that the adoption of this ASU will have on its Condensed Consolidated Financial Statements and related disclosures.

10

Table of Contents

Accounting Guidance Not Yet Elected or Adopted

We consider the applicability and impact of all ASUs. If the ASU is not listed above, it was determined that the ASU was either not applicable or would have an immaterial impact on our Condensed Consolidated Financial Statements and related disclosures.

​

​

NOTE 2. - DISCONTINUED OPERATIONS AND DIVESTITURES

Net (loss) income from discontinued operations for the three and nine months ended September 30, 2026 and 2025 was as follows:

​

​

​

​

​

​

​

​

​

​

​

​

​

​

Three Months Ended

​

Nine Months Ended

​

September 30, 

​

September 30, 

​

2026

  ​ ​ ​

2025

​

2026

  ​ ​ ​

2025

Revenues, net

$

—

​

$

—

​

$

—

​

$

—

Cost of goods sold

​

—

​

​

—

​

​

—

​

​

—

Gross loss

​

—

​

​

—

​

​

—

​

​

—

Operating expenses:

​

​

​

​

​

​

​

​

​

​

​

Sales, general and administrative

​

—

​

​

—

​

​

—

​

​

15

Research and development

​

—

​

​

—

​

​

—

​

​

(402)

Other operating expense (income), net

​

229

​

​

(9,380)

​

​

552

​

​

(8,072)

Total operating expenses (income), net

​

229

​

​

(9,380)

​

​

552

​

​

(8,459)

Operating (loss) income from discontinued operations

​

(229)

​

​

9,380

​

​

(552)

​

​

8,459

Other expense:

​

​

​

​

​

​

​

​

​

​

​

Interest expense

​

—

​

​

128

​

​

—

​

​

372

Total other expense

​

—

​

​

128

​

​

—

​

​

372

(Loss) income from discontinued operations before income taxes

​

(229)

​

​

9,252

​

​

(552)

​

​

8,087

Provision (benefit) for income taxes

​

—

​

​

—

​

​

—

​

​

—

(Loss) income from discontinued operations

$

(229)

​

$

9,252

​

$

(552)

​

$

8,087

​

During the three and nine month periods ended September 30, 2025, the Company settled outstanding obligations which resulted in reversals of previously accrued liabilities of $53 and $474, respectively. Additionally, for the nine month period ended September 30, 2025, Other operating expense (income), net was comprised of $500 provision for credit loss for the GVB promissory note (see below), $293 of impairment charges related to the sale of Needle Rock Farms land property offset by $9,500 related to the Dorchester insurance settlement.

Effective June 24, 2024, GVB Biopharma (“GVB”), the Company’s former subsidiary, made a scheduled principal and interest payment against the Company’s prior outstanding indebtedness to JGB under the former Senior Secured Credit Facility, reducing the Company’s total outstanding principal indebtedness with JGB by $1,500. The remaining $500 payable by GVB under the 2023 GVB Promissory Note was initially extended to December 31, 2024, and subsequently to March 31, 2025.  As of March 31, 2025, the 2023 GVB Promissory Note was in default with respect to payment at maturity of the contractual term and accordingly an allowance for credit loss was initially recorded as of March 31, 2025 in the amount of $500.  

11

Table of Contents

In connection with the September 18, 2025 full repayment of the Senior Secured Credit Facility, the Company entered into a new 2025 GVB Promissory Note with GVB in the amount of $500, payable in installments of $100 each on November 1, 2025, January 1, 2026 and February 1, 2026, with the remaining balance of $200 payable over a term of 31 monthly installments thereafter. The Company has received payments totaling $125 on the 2025 GVB Promissory Note through September 30, 2026. All other payments remain outstanding, triggering the 2025 GVB Promissory Note default provisions and accrual of penalty interest. As of September 30, 2026, the Company continues to maintain a full allowance for credit loss against the 2025 GVB Promissory Note.

​

Cash flow information from discontinued operations for the nine months ended September 30, 2026 and 2025 was as follows:

​

​

​

​

​

​

​

​

​

Nine Months Ended

​

​

September 30, 

​

​

2026

  ​ ​ ​

2025

​

Cash (used in) provided by operating activities

$

(577)

​

$

1,209

​

Cash provided by investing activities

$

25

​

$

770

​

​

​

​

​

​

​

​

Depreciation and amortization

$

-

​

$

-

​

Capital expenditures

$

-

​

$

-

​

​

​

​

NOTE 3. – INVENTORIES

Inventories at September 30, 2026 and December 31, 2025 consisted of the following:

​

​

​

​

​

​

​

​

​

  ​ ​ ​

September 30, 

  ​ ​ ​

December 31, 

​

  ​ ​ ​

2026

  ​ ​ ​

2025

Raw materials

​

$

4,278

​

$

4,213

Work in process

​

​

—

​

​

—

Finished goods

​

 

79

​

​

113

​

​

$

4,357

​

$

4,326

​

As of September 30, 2026 and December 31, 2025, leaf inventory was valued within raw materials at $2,788 and $2,334, respectively.

​

​

​

12

Table of Contents

NOTE 4. – INTANGIBLE ASSETS, NET 

Intangible Assets, Net

Our intangible assets, net at September 30, 2026 and December 31, 2025 consisted of the following:

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

Gross

​

Accumulated

​

​

​

​

 

Net Carrying

September 30, 2026

  ​ ​ ​

Carrying Amount

  ​ ​ ​

Amortization

​

Impairment

​

 

Amount

Definite-lived:

​

​

​

​

​

​

​

​

​

​

​

​

Patent

​

$

2,092

​

$

(1,698)

​

$

—

​

$

394

License fees

​

 

5,331

​

​

(2,404)

​

​

(39)

​

​

2,888

Total amortizing intangible assets

​

$

7,423

​

$

(4,102)

​

$

(39)

​

$

3,282

Indefinite-lived:

​

 

​

​

​

​

​

​

​

​

​

​

Trademarks

​

​

​

​

​

​

​

​

​

​

$

104

MSA signatory costs

​

​

​

​

​

​

​

​

​

​

​

2,202

License fee for predicate cigarette brand

​

​

​

​

​

​

​

​

​

​

​

50

Total indefinite-lived intangible assets

​

​

​

​

​

​

​

​

​

​

$

2,356

Total intangible assets, net

​

​

​

​

​

​

​

​

​

​

$

5,638

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

Gross

​

Accumulated

 

​

​

​

Net Carrying

December 31, 2025

  ​ ​ ​

Carrying Amount

  ​ ​ ​

Amortization

 

Impairment

​

Amount

Definite-lived:

​

​

​

​

​

​

​

​

​

​

​

​

Patent

​

$

2,985

​

$

(2,461)

​

$

(111)

​

$

413

License fees

​

 

5,331

​

​

(2,174)

​

​

—

​

​

3,157

Total amortizing intangible assets

​

$

8,316

​

$

(4,635)

​

$

(111)

​

$

3,570

Indefinite-lived:

​

 

​

​

​

​

​

​

​

​

​

​

Trademarks

​

​

​

​

​

​

​

​

​

​

$

102

MSA signatory costs

​

​

​

​

​

​

​

​

​

​

​

2,202

License fee for predicate cigarette brand

​

​

​

​

​

​

​

​

​

​

​

350

Total indefinite-lived intangible assets

​

​

​

​

​

​

​

​

​

​

$

2,654

Total intangible assets, net

​

​

​

​

​

​

​

​

​

​

$

6,224

​

During the three and nine months ended September 30, 2026, the Company had disposal costs of $0 and $924, respectively, related to expired and abandoned patent costs that have not yet been granted, of which had a carrying value of $0 at the time of disposal.

For the three and nine months ended September 30, 2026, the Company recorded $339 of impairment charges related to predicate licenses, including $300 for indefinite-lived license fees and $39 for definite-lived licenses. During the three and nine months ended September 30, 2025, the Company recorded patent-related impairment charges of $111.

Aggregate intangible asset amortization expense comprises of the following:

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

Three Months Ended

​

Nine Months Ended

​

​

September 30, 

​

September 30, 

​

  ​ ​ ​

2026

  ​ ​ ​

2025

  ​ ​ ​

2026

  ​ ​ ​

2025

Cost of goods sold

​

$

2

​

$

2

​

$

6

​

$

8

Research and development

​

 

92

​

 

109

​

 

274

​

 

320

Total amortization expense

​

$

94

​

$

111

​

$

280

​

$

328

​

13

Table of Contents

Estimated future intangible asset amortization expense based on the carrying value as of September 30, 2026 is as follows:

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

 

2026

 

2027

​

2028

​

2029

​

2030

​

Thereafter

Amortization expense

​

$

91

​

$

361

​

$

326

​

$

239

​

$

237

​

$

2,028

​

​

​

​

​

NOTE 5. - FAIR VALUE MEASUREMENTS

Fair value measurement standards apply to certain financial assets and liabilities that are measured at fair value on a recurring basis (each reporting period). The Company does not have any non-financial assets or liabilities that are measured at fair value on a recurring basis.

Warrants

During 2024, the Company issued the Omnia 2024 warrants to its former subordinated lender in connection with the extinguishment of amounts outstanding under the former Omnia subordinated note. The Omnia 2024 warrants contained a put provision and were previously measured at fair value, resulting in changes in warrant liability fair value being recorded as Other operating expense, net. For the nine-months ended September 30, 2025, the Company recorded $162 loss on change in fair value of warrant liability. The Omnia 2024 warrants were subsequently exercised on September 29, 2025.

The Omnia 2024 warrants were measured at fair value using certain estimated factors which are classified within Level 3 of the valuation hierarchy. Significant unobservable inputs that were used in the fair value measurement of the Company’s warrants include the volatility factor and contingent put option. Significant increases or decreases in the volatility factor would have resulted in a significantly higher or lower fair value measurement. Additionally, a change in probability regarding the put option would have resulted in a significantly higher or lower fair value measurement.

Assets and Liabilities Measured at Fair Value on a Nonrecurring Basis

Fair value standards also apply to certain assets and liabilities that are measured at fair value on a nonrecurring basis. During the three and nine months ended September 30, 2026 and 2025, the Company did not have any financial assets or liabilities measured at fair value on a non-recurring basis.

​

​

​

​

​

​

​

NOTE 6. – EQUITY-BASED COMPENSATION

The Company maintains an Omnibus Incentive Plan that was approved by the Company’s shareholders and is administered by the Compensation Committee of the Company’s Board of Directors. The Omnibus Incentive Plan provides for the granting of stock options, time and performance based restricted stock units (“RSUs”), among other awards to service providers, employees and non-employee directors. As of September 30, 2026, the Company had available 3,772,857 shares remaining for future awards under its Omnibus Incentive Plan.

14

Table of Contents

Compensation Expense – The Company recognized the following compensation costs, net of actual forfeitures, related to RSUs and stock options:

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

Three Months Ended

​

Nine Months Ended

​

​

​

September 30, 

​

September 30, 

​

​

  ​ ​ ​

2026

  ​ ​ ​

2025

  ​ ​ ​

2026

  ​ ​ ​

2025

​

Sales, general, and administrative

​

$

203

​

$

85

​

$

605

​

$

193

​

Cost of goods sold

​

​

7

​

​

1

​

​

20

​

​

18

​

Research and development

​

 

18

​

 

6

​

 

53

​

 

14

​

Total equity-based compensation

​

$

228

​

$

92

​

$

678

​

$

225

​

​

Additionally, during the three and nine months ended September 30, 2026, the Company recognized $147 and $207, respectively of non-employee equity compensation related to the issuance of 15 shares for marketing and consulting services, and issued an additional 1,036 shares for additional services through December 2026 with $88 of remaining unrecognized non-employee equity compensation expense.

Restricted Stock Units – We typically grant RSUs to employees and non-employee directors. The following table summarizes the changes in unvested RSUs from January 1, 2026 through September 30, 2026:

​

​

​

​

​

​

​

​

​

Unvested RSUs

​

​

​

​

Weighted

​

​

​

​

Average

​

​

Number of

​

Grant-date

​

  ​ ​ ​

Shares

  ​ ​ ​

Fair Value

​

​

​

​

$ per share

Unvested at January 1, 2026

 

39

​

$

36,099.20

Vested

​

(1)

​

​

426,474.00

Unvested at March 31, 2026

​

38

​

$

34,557.56

Forfeited

​

(1)

​

​

445,102.44

Unvested at June 30, 2026

​

37

​

$

34,221.16

Unvested at September 30, 2026

​

37

​

$

34,221.16

​

The fair value of RSUs that vested during the nine months ended September 30, 2026 was approximately $1, based on the stock price at the time of vesting. As of September 30, 2026, unrecognized compensation expense for RSUs amounted to $503 which is expected to be recognized over a weighted average period of approximately 1.9 years.

Stock Options – Our outstanding stock options were valued using the Black-Scholes option-pricing model on the date of the award. The following table summarizes the status and activity of stock options from January 1, 2026 through September 30, 2026.

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

Weighted

​

​

​

​

​

​

​

Weighted

​

Average

​

​

​

​

​

​

​

Average

​

Remaining

​

Aggregate

​

​

Number of

​

Exercise

​

Contractual

​

Intrinsic

​

  ​ ​ ​

Options

  ​ ​ ​

Price

  ​ ​ ​

Term

  ​ ​ ​

Value

​

​

​

​

$ per share

​

​

​

​

​

​

Outstanding at January 1, 2026

 

83

​

$

37,531.22

 

9.8

years

 

$

—

Outstanding at March 31, 2026

 

83

​

$

37,531.22

 

9.6

years

 

$

—

Forfeited

​

(1)

​

​

804,402.00

​

​

​

​

​

—

Outstanding at June 30, 2026

​

82

​

$

37,112.46

​

9.3

years

​

$

—

Outstanding at September 30, 2026

​

82

​

$

37,112.46

​

9.1

years

​

$

—

Exercisable at September 30, 2026

 

12

​

$

399,545.18

 

8.7

years

 

$

—

​

The intrinsic value of a stock option is the amount by which the current market value or the market value upon exercise of the underlying stock exceeds the exercise price of the option.

15

Table of Contents

As of September 30, 2026, unrecognized compensation expense for stock options amounted to $1,204, which is expected to be recognized over a weighted average period of approximately 1.9 years.

​

NOTE 7. – NOTES AND LOANS PAYABLE

The table below outlines our notes and loans payable balances as of September 30, 2026 and December 31, 2025:

​

​

​

​

​

​

​

​

​

​

September 30, 

​

December 31, 

​

  ​ ​ ​

2026

  ​ ​ ​

2025

Insurance loans payable

​

$

289

​

$

93

NCSU promissory note

​

​

532

​

​

615

Total notes and loans payable

​

​

821

​

​

708

Total current notes and loans payable

​

​

(405)

​

​

(204)

Total long-term notes and loans payable

​

$

416

​

$

504

​

Insurance loans payable

During the second quarter of 2026, the Company renewed its Director and Officer (“D&O”), property and general liability insurances for a one-year policy premium totaling $802. The Company paid $161 as a premium down payment and financed the remaining $641 of policy premiums over nine months at a 6.05% annual percentage rate.

During the second quarter of 2025, the Company renewed its D&O, property and general liability insurances for a one-year policy premium totaling $1,023. The Company paid $205 as a premium down payment and financed the remaining $818 of policy premiums over nine months at a 6.6% annual percentage rate.

NCSU Promissory Note

On October 31, 2025, the Company entered into a note payable with NCSU in the amount of $632 at 7% simple fee interest rate payable in equal installments over 60 months. The note payable was issued as settlement for all remaining outstanding obligations owed to NCSU related to license fees, annual royalties, and intellectual property and patent maintenance.

Estimated future principal payments to be made under the above notes and loans payable as of September 30, 2026 are as follows:

​

​

​

​

2026

​

$

245

2027

​

​

191

2028

​

​

127

2029

​

​

137

2030

​

​

121

Total

​

$

821

​

​

16

Table of Contents

​

NOTE 8. – REVENUE RECOGNITION

The Company’s revenues are derived primarily from contract manufacturing organization (“CMO”) customer contracts that consist of obligations to manufacture the customers’ branded filtered cigars and cigarettes. Additional revenues are generated from sale of the Company’s proprietary low nicotine content cigarettes, sold under the brand name VLN®, and Pinnacle® branded products. The Company does not have significant intra-entity sales or transfers.

The Company recognizes revenue when it satisfies a performance obligation by transferring control of the product to a customer. For certain CMO contracts, the performance obligation is satisfied over time as the Company determines, due to contract restrictions, it does not have an alternative use of the product and it has an enforceable right to payment as the product is manufactured. The Company recognizes revenue under those contracts at the unit price stated in the contract based on the units manufactured for each customer and is recognized net of cash discounts, rebates, royalties, and sales returns and allowances. There was no allowance for discounts or returns as of September 30, 2026 and December 31, 2025. Consideration payable to the customer for royalties is recorded as an offset of the transaction price with a corresponding contract liability.

Disaggregation of Revenue

The Company’s net revenue is derived from customers located primarily in the United States and is disaggregated by the timing of revenue. Revenue recognized from tobacco products transferred to customers over time represented substantially all net revenue for the three and nine months ended September 30, 2026 and 2025.

The following table presents net revenue by product line:

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

Three Months Ended

​

​

Nine Months Ended

​

​

September 30, 

​

​

September 30, 

​

  ​ ​ ​

2026

​

2025

​

​

2026

​

2025

Contract manufacturing

​

​

​

​

​

​

​

​

​

​

​

​

​

Cigarettes

​

$

3,930

​

$

2,520

​

​

$

9,073

​

$

10,249

Filtered cigars

​

​

674

​

​

1,282

​

​

​

2,240

​

​

3,704

Other tobacco products

​

​

123

​

​

-

​

​

​

361

​

​

88

Total contract manufacturing

​

​

4,727

​

​

3,802

​

​

​

11,674

​

​

14,041

VLN®

​

​

32

​

​

209

​

​

​

55

​

​

9

Total product line revenues

​

$

4,759

​

$

4,011

​

​

$

11,729

​

$

14,050

​

The following table presents net revenues by significant customers, which are defined as any customer who individually represents 10% or more of disaggregated product line net revenues:

​

​

​

​

​

​

​

​

​

​

Three Months Ended

​

​

September 30, 

​

  ​ ​ ​

2026

​

2025

Customer A

​

74.19

%

​

52.92

%

Customer B

​

12.55

%

​

20.18

%

Customer C

​

13.26

%

​

14.42

%

All other customers

​

-

​

​

12.48

%

​

​

​

​

​

​

​

​

​

17

Table of Contents

​

​

Nine Months Ended

​

​

September 30, 

​

​

2026

​

2025

Customer A

​

68.11

%

​

62.29

%

Customer B

​

14.32

%

​

10.60

%

Customer C

​

15.64

%

​

10.22

%

All other customers

​

1.93

%

​

16.89

%

​

Contract Assets and Liabilities

Unbilled receivables (contract assets) represent revenues recognized for performance obligations that have been satisfied but have not been billed. These receivables are included as Accounts receivable, net on the Condensed Consolidated Balance Sheets. Customer payment terms vary depending on the terms of each customer contract, but payment is generally due prior to product shipment or within credit terms up to 30 days after shipment. Deferred income relates to down payments received from customers in advance of satisfying a performance obligation and is included as Contract liabilities on the Condensed Consolidated Balance Sheets.

Total contract assets and contract liabilities are as follows:

​

​

​

​

​

​

​

​

​

​

September 30, 

​

December 31, 

​

  ​ ​ ​

2026

  ​ ​ ​

2025

Unbilled receivables

 

$

3,544

 

$

2,930

Consideration payable to the customer

 

​

(1,037)

 

​

(1,388)

Deferred income

​

​

—

​

​

(333)

Net contract assets

​

$

2,507

​

$

1,209

​

During the nine months ended September 30, 2026 and 2025, the Company recognized $242 and $0 of revenue that was included in the deferred income contract liability balance as of December 31, 2025 and 2024, respectively. There was no revenue recognized for the three months ended September 30, 2026 and 2025. The remaining balance at December 31, 2025 of $91 was reclassified from Deferred income during the nine months ended September 30, 2026.

​

​

​

NOTE 9. - SEGMENT AND GEOGRAPHIC INFORMATION

​

The Company has organized its business as a single reportable segment (“Reporting Segment”), tobacco, as it operates and derives all revenues from its tobacco operations and products. This segment structure reflects the financial information and reports used by the Company’s management, specifically its Chief Operating Decision Maker (“CODM”), to make decisions regarding the Company’s business, including resource allocations and performance assessments. The Company’s Chief Executive Officer serves as the CODM. The accounting policies of the Reporting Segment are the same as those described in the summary of significant accounting policies. See Note 1 for additional information about the Company's business and significant accounting policies.

Consolidated net income (loss) from continuing operations, as presented on the Company's Condensed Consolidated Statements of Operations and Comprehensive Loss is a metric utilized by the CODM to assess the Reporting Segment's performance and allocate resources. Total consolidated assets as presented on the Company's Condensed Consolidated Balance Sheets are used to measure the Reporting Segment's assets.

The CODM uses Consolidated net income (loss) from continuing operations to evaluate profitability generated from segment assets in determining the strategic decisions of the Company with respect to utilizing its assets. Consolidated net income (loss) from continuing operations is also used to monitor budget versus actual results.

18

Table of Contents

The following table presents revenues and significant segment expenses from continuing operations for the three and nine months ended September 30, 2026 and 2025:

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

Three Months Ended

​

Nine Months Ended

​

​

September 30, 

​

September 30, 

​

  ​ ​ ​

2026

  ​ ​ ​

2025

  ​ ​ ​

2026

  ​ ​ ​

2025

Consolidated net revenue

​

$

4,759

​

$

4,011

​

$

11,729

​

$

14,050

Less:

​

​

​

​

​

​

​

​

​

​

​

​

Cost of goods sold

​

​

1,543

​

​

2,432

​

​

4,865

​

​

7,930

Excise taxes

​

​

2,658

​

​

2,513

​

​

7,009

​

​

8,049

Selling, general and administration

​

​

2,451

​

​

1,849

​

​

7,271

​

​

5,766

Research and development

​

​

137

​

​

84

​

​

526

​

​

262

Depreciation and amortization

​

​

207

​

​

234

​

​

623

​

​

693

Other segment items (1)

​

​

310

​

​

128

​

​

236

​

​

240

Interest expense

​

​

17

​

​

534

​

​

47

​

​

1,443

Segment net loss from continuing operations

​

$

(2,564)

​

$

(3,763)

​

$

(8,848)

​

$

(10,333)

(1) Other segment items include: other operating expenses, other expense, interest income, and provision for income taxes.

​

The Company recognized the following depreciation and amortization costs from continuing operations:

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

Three Months Ended

​

Nine Months Ended

​

​

September 30, 

​

September 30, 

​

  ​ ​ ​

2026

  ​ ​ ​

2025

  ​ ​ ​

2026

  ​ ​ ​

2025

Cost of goods sold

​

$

109

​

$

123

​

$

330

​

$

366

Research and development

​

​

4

​

​

—

​

​

13

​

​

—

Total depreciation from continuing operations

​

$

113

​

$

123

​

$

343

​

$

366

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

Three Months Ended

​

Nine Months Ended

​

​

September 30, 

​

September 30, 

​

  ​ ​ ​

2026

  ​ ​ ​

2025

  ​ ​ ​

2026

  ​ ​ ​

2025

Cost of goods sold

​

$

2

​

$

2

​

$

6

​

$

8

Research and development

​

​

92

​

​

109

​

​

274

​

​

320

Total amortization from continuing operations

​

$

94

​

$

111

​

$

280

​

$

328

​

Geographic Area Information

For the three and nine months ended September 30, 2026 and 2025, substantially all third-party sales of product are shipped to customers in the United States. Additionally, as of September 30, 2026 and December 31, 2025, all long-lived assets are physically located or domiciled in the United States.

19

Table of Contents

​

NOTE 10. – CAPITAL RAISES AND WARRANTS FOR COMMON STOCK

The following table summarizes the Company’s warrant activity from January 1, 2026 through September 30, 2026:

​

​

​

​

Warrants outstanding at January 1, 2026

​

637

Issued

​

4,026

Warrants outstanding at March 31, 2026

​

4,663

Issued

​

4,615

Anti-dilution adjustment

​

47,454

Exercised

​

(4,670)

Warrants outstanding at June 30, 2026

​

52,062

Exercised

​

(52,062)

Warrants outstanding at September 30, 2026

​

—

​

The incremental value of modifications to financial instruments, such as warrants or convertible preferred stock, is determined based on Monte-Carlo and Black-Scholes valuation models. Amounts recorded as Deemed dividends in determining Net loss available to common shareholders in the Condensed Consolidated Statements of Operations and Comprehensive Loss are as follows:

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

Three Months Ended

​

​

Nine Months Ended

​

​

September 30, 

​

​

September 30, 

​

  ​ ​ ​

2026

​

2025

​

​

2026

​

2025

Total deemed dividends

​

$

-

​

$

-

​

​

$

18,134

​

$

-

​

​

20

Table of Contents

June 2026 Warrant Inducement and Amendment

On June 8, 2026, the Company commenced a warrant inducement offering (the “June 2026 Warrant Inducement”) with the holders of certain outstanding warrants to purchase up to an aggregate of 4,609 shares of common stock (collectively, the “June 2026 Existing Warrants”), which June 2026 Existing Warrants are exercisable at an exercise price of $4,141.20. The Company offered the holders of the June 2026 Existing Warrants an inducement period whereby the Company agreed to issue new warrants (the “June 2026 Inducement Warrants”) to purchase up to a number of shares of common stock equal to 100% of the number of shares of common stock issued pursuant to the exercise by the holders of the June 2026 Existing Warrants, for cash, at a reduced exercise price equal to $536.62. Each holder agreed to exercise all of their June 2026 Existing Warrants immediately. The Company received aggregate gross cash proceeds of approximately $463 after redemption of $2,010 or 2,010 shares of Series B Preferred Stock from the exercise of the June 2026 Existing Warrants.

To account for the redemption of Series B convertible preferred stock in accordance with ASC 260-10-S99-2, the Company recorded a reduction of Capital in excess of par value of $1,140 to extinguish the carrying value of the Series B convertible preferred stock and a dividend to the holders of the Series B convertible preferred stock of $870, which is a deduction in net income (loss) to arrive at income (loss) available to common shareholders (see Note 11 “Loss Per Common Share”).

The Company measured the fair value of the June 2026 Existing Warrants before and after the modification to decrease the cash exercise price, and concluded there was an increase in fair value of $540 recorded as a deemed dividend.

The provisions of the June 2026 Inducement Warrants regarding stock combination events were triggered as a result of the 1-for-20 reverse stock split on June 12, 2026. The anti-dilution adjustment resulted in the issuance of an additional 47,454 Inducement Warrants and a deemed dividend from issuance of the Inducement Warrants of $17,005. Stockholder approval for issuance and terms of the June 2026 Inducement Warrants was obtained at the August 5, 2026 Special Meeting of the Stockholders.

On August 13, 2026, the Company entered into an amendment with the holders of all of the outstanding June 2026 Inducement Warrants whereby the exercise price was reduced to $21.32 and to allow all of the June 2026 Inducement Warrants to be exercised on a cashless basis. Following the amendment, all 52,062 warrants were exercised on a cashless basis for an aggregate of 47,285 shares of common stock and as of September 30, 2026, 38,870 of such shares remain held in abeyance, and subsequently all shares were issued as common stock with no shares remaining in abeyance. The Company determined the fair value of the June 2026 Inducement Warrants immediately prior to and following the amendment using Black Scholes methodology and concluded no change in fair value occurred.

March 2026 Series B Convertible Preferred Stock Offering

On March 20, 2026, the Company and certain investors entered into a securities purchase agreement with respect to the offer and sale of $20,000 of shares of Series B Convertible Preferred Stock, stated value $1,000 per share (the “Series B convertible preferred stock”), initially convertible into shares of the Company’s common stock at an initial conversion price of $4,141.20 (subject to adjustment in certain circumstances with a floor price of $828.24) and, alternatively, at a 15% discount to the lowest daily volume-weighted average price (“VWAP”) during the prior 20 trading days (the “Alternative Conversion Price”) and warrants to purchase shares of common stock pursuant to a registered direct offering. The Company has the ability to reset the fixed conversion price (lower), subject to board approval and the floor price. Stockholder approval for the offering was obtained at the February 20, 2026 Special Meeting of the Stockholders.

21

Table of Contents

At the initial closing, the investors purchased $16,000 of shares of Series B convertible preferred stock and warrants. The remaining 4,000 shares of Series B Preferred Stock and warrants are expected to be delivered at second closings, of which 25 shares have been purchased through September 30, 2026. The investors may request the second closing at any time until the one-year anniversary of the initial closing date and we may require the second closing at any time until the one-year anniversary of the initial closing date by individual investor once less than 50% of such Investor’s Series B convertible preferred stock purchased at the initial closing remains outstanding and certain equity conditions have been satisfied for at least 7 of the prior 10 trading days, including: (1) the common stock closes above 2.5 times the floor price and (2) the daily dollar trading volume of the Common Stock exceeds $500. The warrants are immediately exercisable at an exercise price of $4,141.20 per share of common stock and expire on the date that is five years after issuance. In addition, the Company issued placement agent warrants to purchase an aggregate of 163 shares of common stock with substantially the same terms as the Warrants, except that the exercise price of the Placement Agent Warrants is $4,555.32.

The Company used the net proceeds from the offering to repurchase at par all of the shares of outstanding Series A convertible preferred stock issued in August 2025 in the amount of $9,650.  The balance of the net proceeds from the offering was approximately $5,680, after deducting placement agent cash fees but before any other offering expenses.  

August 2025 Series A Convertible Preferred Stock Offering

On August 22, 2025, the Company and certain investors entered into a securities purchase agreement with respect to the offer and sale of $10,650 of shares of Series A Convertible Preferred Stock, stated value $1,000 per share (the “Series A convertible preferred stock”), initially convertible into an aggregate of 280 shares of the Company’s common stock at an initial conversion price of $38,106 (subject to adjustment in certain circumstances with a floor price of $6,855.60) and warrants to purchase shares of Common Stock pursuant to a registered direct offering. The Investors purchased $10,650 of shares of Series A convertible preferred stock and warrants. The warrants are immediately exercisable at an exercise price of $34,278 per share of common stock and expire on the date that is five years after issuance. The net proceeds to the Company from the offering was $9,893. In addition, the Company issued placement agent warrants to purchase an aggregate of 33 shares of common stock with substantially the same terms as the warrants, except that the exercise price of the placement agent warrants is $37,758. Following the offering, 1,000 shares of Series A Preferred Stock were converted into 27 shares of common stock.

On December 17, 2025, the Company entered into an Omnibus Amendment and Waiver (the “Amendment Agreement”) with the holders of the outstanding Series A convertible preferred stock to amend the Series A convertible preferred stock, the warrants and certain placement agent warrants issued in connection with the August 2025 offering described above.

Pursuant to the Amendment Agreement, the Company and the holders agreed to provide an alternative conversion feature to the Certificate of Designation whereby the Series A convertible preferred stock can be converted at a conversion price equal to 85% of the lowest VWAP in any of the twenty trading days preceding the conversion.  Pursuant to the Amendment Agreement, the Company also agreed to provide certain anti-dilution adjustments to the exercise price of the warrants and placement agent warrants to provide protection against future dilutive issuances.

Following execution of the Amendment Agreement, the Company re-evaluated conclusions on classification and embedded features, resulting in no changes from the date of issuance of the Series A convertible preferred stock, as further described below.  The impacts of the Amendment Agreement are accounted for as an extinguishment, as the fair value of the instruments before and after modification increased by greater than 10%, resulting in the incremental value being recorded within Capital in excess of par value as a deemed dividend of $4,679 recorded in the period ended December 31, 2025.

Subsequent to December 31, 2025, stockholder approval for the provisions of the Amendment Agreement was obtained at the February 20, 2026 Special Meeting of the Stockholders.  

22

Table of Contents

On March 24, 2026, in connection with an offering of newly issued Series B convertible preferred stock, the Company redeemed all 9,650 shares of Series A convertible preferred stock at par in the amount of $9,650.  The Company evaluated the redemption to determine whether it is treated as an exchange transaction, assessing qualitative factors, to conclude whether the accounting would be a modification or extinguishment.  The Company believes the changes in fixed conversion price and floor price of the Series B convertible preferred stock are so significant that the accounting should be an extinguishment of the Series A convertible preferred stock and issuance of new Series B convertible preferred stock. Therefore, in accordance with ASC 260-10-S99-2, the Company recorded a reduction of Capital in excess of par value of $2,734 to extinguish the carrying value of the Series A convertible preferred stock and a dividend to the holders of the Series A convertible preferred stock of $6,916, which is a deduction in net income (loss) to arrive at income (loss) available to common shareholders (see Note 11 “Loss Per Common Share”).

Mezzanine Classification

ASC 480-10-S99-3A(2) of the SEC's Accounting Series Release No. 268 ("ASR 268") requires preferred securities that are redeemable for cash or other assets to be classified outside of permanent equity if they are redeemable (i) at a fixed or determinable price on a fixed or determinable date, (ii) at the option of the holder, or (iii) upon the occurrence of an event that is not solely within the control of the issuer. Preferred securities that are mandatorily redeemable are required to be classified by the issuer as liabilities whereas under ASR 268, a company should classify a preferred security whose redemption is contingent on an event not entirely in control of the issuer as mezzanine equity. The Series A convertible preferred stock is redeemable at the option of the holder if "shareholder approval" (as defined in the agreements) is not obtained, which is not solely within control of the Company, and accordingly, the Company determined that mezzanine treatment is appropriate for the Series A convertible preferred stock. The Series A convertible preferred stock was initially measured at the amount of total proceeds less any offering costs and proceeds allocated to the accompanying warrants based on relative fair value, and was previously presented as such in the Condensed Consolidated Balance Sheets. Following stockholder approval at the February 20, 2026 Special Meeting of the Stockholders, the Company reclassified the carrying value of the Series A convertible preferred stock from mezzanine equity to permanent equity in accordance with ASC 480-10-S99-3A.

Further, upon issuance the Company evaluated all embedded features against an equity-like host and concluded none of the embedded features identified within the Series A and the newly issued Series B convertible preferred stock that may require bifurcation as they are either deemed clearly and closely related or not net settleable as a result of a lack of an active market.

Convertible preferred stock transaction activity is summarized in the table below:

​

​

​

​

​

​

​

​

​

​

​

Convertible Preferred Stock Shares

​

Weighted Average Conversion Price

​

Common Shares Issued from Conversions

Convertible preferred stock outstanding at January 1, 2026

​

9,650

​

​

​

​

​

Redemption of Series A Convertible Preferred Stock

​

(9,650)

​

​

​

​

​

Issuance of Series B Convertible Preferred Stock

​

16,000

​

​

​

​

​

Conversion of Series B Convertible Preferred Stock

​

(230)

​

$

2,934.80

​

85

Convertible preferred stock outstanding at March 31, 2026

​

15,770

​

​

​

​

​

Redemption of Series B Convertible Preferred Stock

​

(2,010)

​

​

​

​

​

Issuance of Series B Convertible Preferred Stock

​

25

​

​

​

​

​

Conversion of Series B Convertible Preferred Stock

​

(5,280)

​

$

1,504.52

​

3,527

Convertible preferred stock outstanding at June 30, 2026

​

8,505

​

​

​

​

​

Convertible preferred stock outstanding at September 30, 2026

​

8,505

​

​

​

​

​

​

23

Table of Contents

April 2025 Warrant Inducement and Amendment

On April 29, 2025, the Company commenced a warrant inducement offering with the holders of outstanding warrants to purchase 28 shares of common stock (the “April 2025 Existing Warrants”). The Company offered the holders of the Existing Warrants an inducement period whereby the Company agreed to issue new warrants (the “Inducement Warrants”) to purchase up to a number of shares of common stock equal to 100% of the number of shares of common stock issued pursuant to the exercise by the holders of the Existing Warrants, for cash, at a reduced exercise price. Each holder agreed to exercise 60% of their Existing Warrants immediately (the “Initial Exercise”) and would exercise the remaining 40% within 30 calendar days following the Effectiveness Date (as defined in the agreements), provided that the Company’s stock price at such time equals or exceeds 90% of the Nasdaq Minimum Price on that date (the “Additional Exercise”).

The net proceeds to the Company from the Initial Exercise, after deducting placement agent fees and the Company’s offering expenses were $5,075. In connection with the Initial Exercise, the Company issued 18 Inducement Warrants. Of the aggregate net proceeds, the Company was obligated under the Debentures of the convertible senior secured credit facility to repay outstanding debt in the amount of $1,017. The Company also measured the fair value of the April 2025 Existing Warrants before and after the modification to decrease the cash exercise price and concluded there was no incremental fair value to be recorded as issuance costs due to the alternative cashless exercise features of the warrants.

Additionally, on April 29, 2025, the Company entered into amendments with the holders of the outstanding warrants issued on October 24, 2024, which adjusted the provisions of the warrants regarding recapitalization events, stock dividends, stock splits, stock combinations, reclassifications, reorganizations or similar events affecting the Company’s common stock. The anti-dilution adjustment resulted in the issuance of an additional 82 October 2024 PIPE Warrants and October 2024 PIPE Placement Agent warrants.

ATM Offering

On November 4, 2025, the Company established an at-the-market common equity offering program (“ATM Program”), through which it had the ability to offer and sell shares of common stock having an aggregate gross sales price of up to $25,000, which program was reduced to a maximum of $6,400 on May 1, 2026. The Company will pay a 3.00% sales commission based on the gross proceeds of the sales price per share of common stock sold and incurred initial offering costs of $130, deducted from gross proceeds. See Note 13 “Subsequent Events.” The following table shows the number of shares sold under the ATM Program:

​

​

​

​

​

​

​

​

​

​

Three Months Ended

​

Nine Months Ended

​

​

September 30, 

​

September 30, 

​

  ​ ​ ​

2026

  ​ ​ ​

2026

Number of common shares issued

​

​

—

​

​

42

Weighted average sale price per share

​

$

—

​

$

5,231.60

Gross proceeds

​

$

—

​

$

200

Net proceeds

​

$

—

​

$

64

​

​

​

24

Table of Contents

NOTE 11. – EARNINGS (LOSS) PER COMMON SHARE

The following table sets forth the computation of basic and diluted loss per common share for the three and nine months ended September 30, 2026 and 2025, respectively. Outstanding convertible preferred stock, warrants, options and RSUs are excluded from the calculation of diluted earnings per share as the effect was antidilutive to consolidated net loss.

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

Three Months Ended

​

Nine Months Ended

​

​

September 30, 

​

September 30, 

​

  ​ ​ ​

2026

  ​ ​ ​

2025

  ​ ​ ​

2026

  ​ ​ ​

2025

​

​

(in thousands, except for per-share data)

Net loss from continuing operations

​

$

(2,564)

​

$

(3,763)

​

$

(8,848)

​

$

(10,333)

Net (loss) income from discontinued operations

​

​

(229)

​

​

9,252

​

​

(552)

​

​

8,087

Net (loss) income

​

​

(2,793)

​

​

5,489

​

​

(9,400)

​

​

(2,246)

Deemed dividends

​

​

—

​

​

—

​

​

(18,134)

​

​

—

Dividend for redemption of Series A Convertible Preferred Stock

​

​

—

​

​

—

​

​

(6,916)

​

​

—

Dividend for redemption of Series B Convertible Preferred Stock

​

​

—

​

​

—

​

​

(870)

​

​

—

Net (loss) income available to common shareholders

​

$

(2,793)

​

$

5,489

​

$

(35,320)

​

$

(2,246)

​

​

​

​

​

​

​

​

​

​

​

​

​

Weighted average common shares outstanding - basic and diluted*

​

​

11,271

​

​

191

​

​

5,146

​

​

70

​

​

​

​

​

​

​

​

​

​

​

​

​

Basic and diluted loss per common share from continuing operations

​

$

(227.49)

​

$

(19,701.57)

​

$

(1,719.39)

​

$

(147,614.29)

Basic and diluted (loss) income per common share from discontinued operations

​

$

(20.32)

​

$

48,439.79

​

$

(107.27)

​

$

115,528.57

Basic and diluted (loss) income available to common shareholders per common share

​

$

(247.80)

​

$

28,738.22

​

$

(6,863.58)

​

$

(32,085.71)

​

​

​

​

​

​

​

​

​

​

​

​

​

Anti-dilutive shares are as follows as of September 30:

​

​

​

​

​

​

​

​

​

​

​

​

Warrants

​

​

—

​

​

657

​

​

—

​

​

657

Options

​

​

82

​

​

21

​

​

82

​

​

21

Restricted stock units

​

​

37

​

​

18

​

​

37

​

​

18

​

​

​

119

​

​

696

​

​

119

​

​

696

​

​

​

​

​

​

​

​

​

​

​

​

​

*For the three and nine months ended September 30, 2026, 38,870 shares of common stock held in abeyance were excluded from the computation of weighted-average common shares outstanding.

​

​

​

​

25

Table of Contents

NOTE 12. - COMMITMENTS AND CONTINGENCIES

License agreements and consulting agreements – The Company has entered into various consulting and license research agreements with various counter parties in connection with the Company’s business objectives. The schedule below summarizes the Company’s commitments, both financial and other, associated with each Agreement. Costs incurred under the license agreements are recorded as an offset to revenue and costs incurred for the consulting agreements are recorded as sales, general and administrative expenses on the Company’s Condensed Consolidated Statements of Operations and Comprehensive Loss.

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

Future Commitments

​

Commitment

 

Counter Party

 

Commitment Type

 

2026

 

2027

 

2028

 

2029

​

2030 & After

​

Total

  ​ ​ ​

License Agreement

​

NCSU

​

Minimum annual royalty

​

$

25

​

$

100

​

$

125

​

$

150

​

$

3,050

​

$

3,450

(1)

Testing Services Agreement

​

NCSU

​

Contract fee

​

​

9

​

​

—

​

​

—

​

​

—

​

​

—

​

​

9

(2)

Consulting Agreements

​

Various

​

Contract fee

​

​

63

​

​

42

​

​

—

​

​

—

​

​

—

​

​

105

(3)

Manufacturing Equipment

​

Various

​

Capital expenditure

​

​

300

​

​

536

​

​

—

​

​

—

​

​

—

​

​

836

(4)

​

​

​

​

​

​

$

397

​

$

678

​

$

125

​

$

150

​

$

3,050

​

$

4,400

​

​

(1)The minimum annual royalty fee is credited against running royalties on sales of licensed products. The Company is also responsible for reimbursing NCSU for actual third-party patent costs incurred, including capitalized patent costs and patent maintenance costs. These costs vary from year to year and the Company has certain rights to direct the activities that result in these costs.
(2)On January 1, 2026, the Company engaged NCSU to perform field testing of low alkaloid tobacco lines.
(3)As a requirement for a modified risk tobacco product and condition of the marketing authorization by the FDA, the Company engaged various consulting firms to conduct post-market studies and research.
(4)The Company entered into an agreement on March 31, 2026, to acquire a new manufacturing equipment, anticipated to be delivered and installed in first half of 2027.

Litigation - The Company is subject to litigation arising from time to time in the ordinary course of its business. The Company does not expect that the ultimate resolution of any pending legal actions will have a material effect on its consolidated results of operations, financial position, or cash flows. However, litigation is subject to inherent uncertainties. As such, there can be no assurance that any pending legal action, which the Company currently believes to be immaterial, will not become material in the future. In accordance with applicable accounting guidance, the Company establishes an accrued liability for litigation and regulatory matters when those matters present loss contingencies that are both probable and estimable. In such cases, there may be an exposure to loss in excess of any amounts accrued. When a loss contingency is not both probable and estimable, the Company does not establish an accrued liability. As a litigation or regulatory matter develops, the Company, in conjunction with any outside counsel handling the matter, evaluates on an ongoing basis whether such matter presents a loss contingency that is probable and estimable. If, at the time of evaluation, the loss contingency related to a litigation or regulatory matter is not both probable and estimable, the matter will continue to be monitored for further developments that would make such loss contingency both probable and estimable. When a loss contingency related to a litigation or regulatory matter is deemed to be both probable and estimable, the Company will establish an accrued liability with respect to such loss contingency and record a corresponding amount of related expenses. The Company will then continue to monitor the matter for further developments that could affect the amount of any such accrued liability. 

Cookies Retail Products Dispute

On October 23, 2024, Cookies Retail Products, LLC (“CRP”) filed a complaint against the Company, a subsidiary of the Company (“PTB”), Cookies Creative Consulting & Promotions, Inc. (“CCC”), Cookies SF, LLC (“CSF”), GMLC WLNS, LLC (“GMLC”) and other defendants, Case No. 24STCV27828, Superior Court of California, County of Los Angeles.

The complaint alleges three counts against all defendants: Count I for Breach of Contract related to a Settlement Agreement entered into between CRP, Paul Rock, CSF, GMLC, CCC and PTB (the “Settlement Agreement”), and a Purchase Agreement entered into between PTB and CRP (the “Purchase Agreement”); Count II for Fraud – False Promise related to the Settlement Agreement and Purchase Agreement; and Count III for Violation of Penal Code Section 496 related to the Purchase Agreement and a Licensing and Distribution Agreement between GMLC, CCC and PTB. CRP is seeking monetary damages.

26

Table of Contents

CRP filed a first amended complaint on March 12, 2025, restating the same three counts. The Company filed a Special Motion to Strike the first amended complaint on March 27, 2025. At an April 28, 2025 hearing, the Court granted the Company’s Special Motion to Strike as to Count II and Count III in CRP’s first amended complaint, leaving only Count I. CRP will not have an opportunity to amend its complaint to replead Count II or Count III. On May 15, 2025, the Court also denied an application that had been filed by CRP for a right to attach order and writ of attachment against PTB.

On November 12, 2025, the Company filed a cross-complaint against Paul and Sameera Rock for Breach of Written Contract and Declaratory Relief.

The Company subsequently filed a Motion for Summary Adjudication seeking the dismissal of CRP’s remaining Count I. The Court issued a ruling denying the Company’s motion on March 6, 2026.

The trial date is January 12, 2027. Discovery is ongoing.

Employee Dispute

On November 19, 2024, a former employee of the Company filed a complaint against the Company, two subsidiaries of the Company, and numerous other former subsidiaries of the Company that were part of the hemp/cannabis division that was divested in December 2023. The complaint was filed in the Circuit Court of the State of Oregon, County of Multnomah, Case No. 24CV55110. The parties have reached an agreement in principle regarding a global resolution of the matter. The contemplated settlement remains subject to the negotiation and execution of definitive documentation and the satisfaction of any conditions contained therein. Under the terms agreed to in principle, the Company paid $55 in addition to contributions from other co-defendants.

​

​

​

NOTE 13. - SUBSEQUENT EVENTS

ATM Offering

On November 4, 2025, the Company established an at-the-market common equity offering program (“ATM Program”), through which it has the ability to offer and sell shares of common stock having an aggregate gross sales price of up to $25,000. The program was reduced to a maximum of $6,400 on May 1, 2026 and subsequently increased on October 23, 2026, whereby the Company filed a prospectus supplement permitting the sale of up to $18,800 shares of the Company’s common stock in its at-the-market offering pursuant to its sales agreement. The remaining capacity as of November 13, 2026 is approximately $13,000. The following table summarizes the Company’s common stock issuances under the ATM program as of November 13, 2026:

​

​

​

​

​

Number of common shares issued

​

​

3,151,300

Weighted average sale price per share

​

$

3.34

Gross proceeds

​

$

10,536

Net proceeds

​

$

10,138

​

The Company used $5,576 of net cash proceeds from the offering to repurchase an equal amount of Series B convertible preferred shares at par. The remaining number of Series B convertible preferred shares outstanding after redemptions is 2,929.

​

​

​

​

​

27

Table of Contents

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

For purposes of this Management’s Discussion and Analysis of Financial Condition and Results of Operations (“MD&A”), references to the “Company,” “we,” “us” or “our” refer to the operations of 22nd Century Group, Inc. and its direct and indirect subsidiaries for the periods described herein.

The following MD&A should be read in conjunction with, our audited consolidated financial statements, the accompanying notes and the MD&A included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2025, as well as our Condensed Consolidated Financial Statements and the accompanying notes included in Item 1 of this Form 10-Q. Note references are to the notes to consolidated financial statements included in Item 1 of this Form 10-Q.

All historical share and per-share amounts reflected throughout this section have been adjusted to reflect prior reverse stock splits. The par value per share of our common stock was not affected.

All figures reported below reflect continuing operations, excluding discontinued operations related to the sale and exit of the Company’s hemp/cannabis business in late 2023, except as noted.

Dollars are in thousands, except per share data or unless otherwise specified.

Forward Looking Statements

Except for historical information, all of the statements, expectations, and assumptions contained herein are forward-looking statements. Forward-looking statements typically contain terms such as “anticipate,” “believe,” “consider,” “continue,” “could,” “estimate,” “expect,” “explore,” “foresee,” “goal,” “guidance,” “intend,” “likely,” “may,” “plan,” “potential,” “predict,” “preliminary,” “probable,” “project,” “promising,” “seek,” “should,” “will,” “would,” and similar expressions. Forward looking statements include, but are not limited to, statements regarding (i) our ability to continue as a going concern, (ii) our ability to become profitable, (iii) our ability to remain listed on NASDAQ (iv) our ability to raise additional funds to continue operations, (v) our financial and operating performance, (vi) our strategic alternatives, including our cost savings initiatives, (vii) our expectations regarding regulatory enforcement (viii) our products, and (ix) the volatility of our common stock. Actual results might differ materially from those explicit or implicit in forward-looking statements. Important factors that could cause actual results to differ materially are set forth in “Risk Factors” herein, in our Annual Report on Form 10-K filed on March 26, 2026 and in our Quarterly Report on Form 10-Q filed on August 14, 2026. We undertake no obligation to publicly update or revise any forward-looking statement as a result of new information, future events, or otherwise, except as otherwise required by law. All information provided in this quarterly report is as of the date hereof, and we assume no obligation to and do not intend to update these forward-looking statements, except as required by law.

Our Business

22nd Century Group, Inc. (NASDAQ: XXII) is a tobacco products company focused on tobacco harm reduction by offering tobacco products with 95% less nicotine, designed to improve health and wellness by giving smokers a choice to control their nicotine consumption. Backed by comprehensive and extensively patented technologies that regulate nicotine biosynthesis activities in the tobacco plant, the Company has pioneered development of high-yield, proprietary reduced nicotine content (“RNC”) tobacco plants and clinically validated RNC cigarette products. The Company received the first and only FDA Modified Risk Tobacco Product (“MRTP”) authorization for a combustible cigarette in December 2021. The Company is a subsequent participating manufacturer under the Master Settlement Agreement ("MSA") and vertically integrated for the production of both its own products and contract manufacturing operations ("CMO"), which consist primarily of branded filtered cigars and conventional cigarettes.

Financial Overview

●Net revenues for the third quarter of 2026 were $4,759, an increase of 18.6% from $4,011 in the prior year period.
oThird quarter 2026 cartons sold decreased to 224 compared to 517 in the comparable prior year period, primarily due to our strategic shift away from high volume and low priced CMO export customers.

28

Table of Contents

●Gross profit for the third quarter of 2026 was $446 compared to a loss of $1,059 in the prior year period representing the benefit of price increases effective July 1, 2026 on its cigarette volume, including higher margin branded products.
●Total operating expenses for the third quarter of 2026 increased to $3,023 compared to $2,153 in the prior year period driven by:
oSales, general and administrative expenses increased to $2,451 compared to $1,849 in the prior year period, primarily driven by higher compensation and benefits, strategic consulting, sales and marketing, travel and entertainment, legal and other expenses offset by lower insurance costs.
oResearch development expenses increased to $233, compared to $193 in the prior year period, mainly driven by higher compensation and benefits and lower contract, IP and other expenses.
oOther operating expenses, net increased to $339, compared to $111 in the prior year period, mainly driven by higher impairment charges on intangible assets, including predicate licenses and patents.
●Operating loss from continuing operations for the third quarter 2026 was $2,577, compared to a loss of $3,212 in the prior year period.
●Net loss from continuing operations in the third quarter of 2026 was $2,564 and basic and diluted loss from continuing operations per common share was $227.49 compared with net loss from continuing operations in the third quarter of 2025 of $3,763, and basic and diluted net loss from continuing operations per common share of $19,701.57.
●As of September 30, 2026, the Company had $3,911 in cash and cash equivalents.

​

Our Financial Results

Three Months Ended September 30, 2026 Compared to Three Months Ended September 30, 2025

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

Three Months Ended

​

​

​

​

​

​

​

September 30

​

​

September 30

​

​

Change

​

  ​ ​ ​

2026

  ​ ​ ​

​

2025

​

​

$

​

%

Revenues, net

​

$

4,759

​

​

$

4,011

​

​

748

​

18.6

Cost of goods sold

​

​

1,655

​

​

​

2,557

​

​

(902)

​

(35.3)

Excise taxes and fees on products

​

​

2,658

​

​

​

2,513

​

​

145

​

5.8

Gross profit (loss)

​

​

446

​

​

​

(1,059)

​

​

1,505

​

(142.1)

Gross loss as a % of revenues, net

​

​

9.4

%

​

​

(26.4)

%

​

​

​

​

Operating expenses:

​

​

​

​

​

​

​

​

​

​

​

​

Sales, general and administrative ("SG&A")

​

​

2,451

​

​

​

1,849

​

​

602

​

32.6

SG&A as a % of revenues, net

​

​

51.5

%

​

​

46.1

%

​

​

​

​

Research and development ("R&D")

​

​

233

​

​

​

193

​

​

40

​

20.7

R&D as a % of revenues, net

​

​

4.9

%

​

​

4.8

%

​

​

​

​

Other operating expense, net ("OOE")

​

​

339

​

​

​

111

​

​

228

​

205.4

Total operating expenses

​

​

3,023

​

​

​

2,153

​

​

870

​

40.4

Operating loss from continuing operations

​

​

(2,577)

​

​

​

(3,212)

​

​

635

​

(19.8)

Operating loss as a % of revenues, net

​

​

(54.2)

%

​

​

(80.1)

%

​

​

​

​

Other (income) expense:

​

​

​

​

​

​

​

​

​

​

​

​

Other expense

​

​

-

​

​

​

33

​

​

(33)

​

(100.0)

Interest income

​

​

(30)

​

​

​

(16)

​

​

(14)

​

87.5

Interest expense

​

​

17

​

​

​

534

​

​

(517)

​

(96.8)

Total other (income) expense, net

​

​

(13)

​

​

​

551

​

​

(564)

​

(102.4)

Loss from continuing operations before income taxes

​

​

(2,564)

​

​

​

(3,763)

​

​

1,199

​

(31.9)

(Benefit) provision for income taxes

​

​

-

​

​

​

-

​

​

-

​

-

Net loss from continuing operations

​

$

(2,564)

​

​

$

(3,763)

​

​

1,199

​

(31.9)

Net loss as a % of revenues, net

​

​

(53.9)

%

​

​

(93.8)

%

​

​

​

​

Net loss per common share from continuing operations (basic and diluted)

​

$

(227.49)

​

​

$

(19,701.57)

​

​

19,474.08

​

(98.8)

​

​

​

​

​

​

​

​

​

​

​

​

​

29

Table of Contents

​

Nine Months Ended September 30, 2026 Compared to Nine Months Ended September 30, 2025

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

Nine Months Ended

​

​

​

​

​

​

​

September 30

​

​

September 30

​

​

Change

​

  ​ ​ ​

2026

  ​ ​ ​

​

2025

​

​

$

​

%

Revenues, net

​

$

11,729

​

​

$

14,050

​

​

(2,321)

​

(16.5)

Cost of goods sold

​

​

5,201

​

​

​

8,304

​

​

(3,103)

​

(37.4)

Excise taxes and fees on products

​

​

7,009

​

​

​

8,049

​

​

(1,040)

​

(12.9)

Gross loss

​

​

(481)

​

​

​

(2,303)

​

​

1,822

​

(79.1)

Gross loss as a % of revenues, net

​

​

(4.1)

%

​

​

(16.4)

%

​

​

​

​

Operating expenses:

​

​

​

​

​

​

​

​

​

​

​

​

Sales, general and administrative ("SG&A")

​

​

7,272

​

​

​

5,766

​

​

1,506

​

26.1

SG&A as a % of revenues, net

​

​

62.0

%

​

​

41.0

%

​

​

​

​

Research and development ("R&D")

​

​

813

​

​

​

583

​

​

230

​

39.5

R&D as a % of revenues, net

​

​

6.9

%

​

​

4.1

%

​

​

​

​

Other operating expense, net ("OOE")

​

​

339

​

​

​

111

​

​

228

​

205.4

Total operating expenses

​

​

8,424

​

​

​

6,460

​

​

1,964

​

30.4

Operating loss from continuing operations

​

​

(8,905)

​

​

​

(8,763)

​

​

(142)

​

1.6

Operating loss as a % of revenues, net

​

​

(75.9)

%

​

​

(62.4)

%

​

​

​

​

Other (income) expense:

​

​

​

​

​

​

​

​

​

​

​

​

Other expense

​

​

-

​

​

​

207

​

​

(207)

​

(100.0)

Interest income

​

​

(104)

​

​

​

(46)

​

​

(58)

​

126.1

Interest expense

​

​

47

​

​

​

1,443

​

​

(1,396)

​

(96.7)

Total other (income) expense, net

​

​

(57)

​

​

​

1,604

​

​

(1,661)

​

(103.6)

Loss from continuing operations before income taxes

​

​

(8,848)

​

​

​

(10,367)

​

​

1,519

​

(14.7)

(Benefit) provision for income taxes

​

​

-

​

​

​

(34)

​

​

34

​

(100.0)

Net loss from continuing operations

​

​

(8,848)

​

​

​

(10,333)

​

​

1,485

​

(14.4)

Net loss as a % of revenues, net

​

​

(75.4)

%

​

​

(73.5)

%

​

​

​

​

Net loss per common share from continuing operations (basic and diluted)

​

$

(1,719.39)

​

​

$

(147,614.29)

​

​

145,894.90

​

(98.8)

​

​

​

​

​

​

​

​

​

​

​

​

​

​

Product line revenue, net

​

​

​

​

​

​

​

​

​

​

​

​

Three Months Ended

​

​

September 30, 

​

​

​

​

  ​ ​ ​

2026

​

2025

​

Change

​

​

$

Cartons

​

$

Cartons

​

$

Cartons

Contract manufacturing

​

​

​

​

​

​

​

​

​

Cigarettes

​

3,930

131

​

2,520

345

​

1,410

(214)

Filtered cigars

​

674

80

​

1,282

168

​

(608)

(88)

Other tobacco products

​

123

12

​

-

-

​

123

12

Total contract manufacturing

​

4,727

223

​

3,802

513

​

925

(290)

VLN®

​

32

1

​

209

4

​

(177)

(3)

Total product line revenues

​

4,759

224

​

4,011

517

​

748

(293)

​

​

​

​

​

​

​

​

​

​

​

30

Table of Contents

​

​

​

​

​

​

​

​

​

​

​

​

Nine Months Ended

​

​

September 30, 

​

​

​

​

​

2026

​

2025

​

Change

​

​

$

Cartons

​

$

Cartons

​

$

Cartons

Contract manufacturing

​

​

​

​

​

​

​

​

​

Cigarettes

​

9,073

342

​

10,249

1,370

​

(1,176)

(1,028)

Filtered cigars

​

2,240

281

​

3,704

498

​

(1,464)

(217)

Other tobacco products

​

361

27

​

88

14

​

273

13

Total contract manufacturing

​

11,674

650

​

14,041

1,882

​

(2,367)

(1,232)

VLN®

​

55

1

​

9

1

​

46

-

Total product line revenues

​

11,729

651

​

14,050

1,883

​

(2,321)

(1,232)

​

For the third quarter ended September 30, 2026, total product line revenues increased to $4,759 from $4,011 in the prior year period and for the nine months ended September 30, 2026, total product line revenues decreased to $11,729 compared to $14,050 in the prior year period as a result of the following:

​

●For the three and nine months ended September 30, 2026, cigarette volume decreased due to our strategic shift away from high volume and low priced CMO export customers as compared to the prior year periods, which accounted for 240 cartons and 986 cartons, respectively. The increase in cigarette revenue in the three months ended September 30, 2026 to $3,930 from $2,520 in the prior year period reflects price increases effective July 1, 2026.

​

●For the three and nine months ended September 30, 2026, filtered cigars net revenues decreased to $674 and $2,240, from $1,282 and $3,704 respectively in the prior comparable periods, reflecting lower volumes as the Company implemented repricing of customer contracts and shifts in its product mix into higher margin branded cigarettes, including natural styles, and VLN® cigarettes. The Company anticipates that it will end production under the majority of its filtered cigar CMO customer contracts at the end of fiscal 2026 in pursuit of its strategy to shift away from high volume and low margin contracts.

​

●Other tobacco products include new moist snuff sales of $121 and $614 for the three and nine months ended September 30, 2026, respectively, compared to none in the prior year comparable periods. These new sales were offset by the reversal of $255 related to obsolete cigarillo products.

​

●VLN® cigarette net revenues reflect additional distribution in metropolitan New York and northern New Jersey in the third quarter of 2026 primarily for our Pinnacle® partner brand VLN® products, offset by current period price promotions targeting expanded awareness, consumer trial and adoption. Additionally, net revenue reflects accruals for product previously sold in prior years that will be returned or exchanged.

​

31

Table of Contents

​

Gross (loss) profit

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

Three Months Ended

 

Nine Months Ended

​

​

September 30

​

September 30

 

September 30

​

September 30

​

  ​ ​ ​

2026

  ​ ​ ​

2025

  ​ ​ ​

2026

​

2025

Gross profit (loss)

​

$

446

​

$

(1,059)

​

$

(481)

​

​

$

(2,303)

​

Percent of Revenues, net

​

 

9.4

%  

 

(26.4)

%

​

(4.1)

%

​

​

(16.4)

%

​

Gross profit for the three months ended September 30, 2026, reflect the benefit of price increases effective July 1, 2026 on its cigarette volume, including higher margin branded products. Gross loss for the nine month period ended September 30, 2026 decreased as compared to the prior year comparable periods benefitting from manufacturing overhead cost savings initiatives implemented by management in second half 2025, price increases, and shifting strategy into higher margin branded products. Additionally, the nine month period ended September 30, 2026 reflected one-time charges for write-off of aged inventory discontinued by our customers of $196, offset by a one-time recovery of excise taxes of $692 related to settlement with states for non-participating manufacturers credits under the master settlement agreement related to prior tax periods.

​

Sales, general and administrative (“SG&A”) expense

​

​

​

​

​

​

​

​

  ​ ​ ​

Changes From Prior Year

​

​

Three Months Ended

​

Nine Months Ended

Compensation and benefits (a)

​

$

375

​

$

1,442

Strategic consulting (b)

​

​

109

​

​

(280)

Legal (c)

​

​

11

​

​

86

Insurance (d)

​

​

(52)

​

​

(117)

Sales and marketing (e)

​

​

88

​

​

114

Travel and entertainment

​

​

24

​

​

53

Other expenses

​

​

47

​

​

208

Net increase in SG&A expenses

​

$

602

​

$

1,506

​

(a) Compensation and benefits expense increased for the three and nine months ended September 30, 2026, compared to the prior year periods due to an increase in sales and marketing headcount, benefit premiums, equity and incentive compensation expense.

(b) Strategic consulting costs increased for the three months ended September 30, 2026, compared to the prior year periods due to increased spending related to investor relation services offset by lower FDA post-market study costs. The decrease of strategic consulting for the nine months period ended September 30, 2026, compared to the prior year periods was due to the decrease in FDA post-market studies, investor relation expenses and accounting related consulting expenses.

(c) Legal expenses increased for the three and nine months ended September 30, 2026 compared to 2025 mainly due to higher tobacco regulatory legal spend compared to the prior year periods.

(d) Insurance costs decreased for the three and nine months ended September 30, 2026 compared to the prior year periods due to lower insurance premiums.

(e) Sales and marketing costs increased for the three and nine months ended September 30, 2026, compared to the prior year periods due to new marketing initiatives and point of sale purchases.

​

32

Table of Contents

Research and development (“R&D”) expense

​

​

​

​

​

​

​

​

  ​ ​ ​

Changes From Prior Year

​

​

Three Months Ended

​

Nine Months Ended

Compensation and benefits (a)

​

$

59

​

$

258

Contract, IP and other expenses (b)

​

​

(19)

​

​

(28)

Net increase in R&D expenses

​

$

40

​

$

230

​

(a)Increased compensation and benefits for the three and nine months ended September 30, 2026, are mainly related to an increase in headcount, benefit premiums and equity compensation expenses in the current year period compared to the prior year periods.
(b)Contract, IP and other expenses decreased for the three months ended September 30, 2026, compared to the prior year period were primarily due to lower amortization expenses and testing expenses for new product development.

Decreased Contract, IP and other expenses for the nine months ended September 30, 2026, compared to the prior year period were due to lower amortization expense offset by increased contract costs.

Other (income) expense

​

​

​

​

​

​

​

​

​

Changes From Prior Year

​

  ​ ​ ​

Three Months Ended

​

Nine Months Ended

Other expense (a)

​

$

(33)

​

$

(207)

Interest income

​

​

(14)

​

​

(58)

Interest expense (b)

​

​

(517)

​

​

(1,396)

Net decrease in other (income) expense

​

$

(564)

​

$

(1,661)

​

​

(a)Other expense decreased for the three and nine months ended September 30, 2026, compared to the same prior year periods, due to a loss resulting from change in fair value of the Omnia 2024 warrant liabilities that did not occur in the current year periods.

​

(b)Decreases in interest expense was a result of repayment of debt obligations on our balance sheet.

​

For the three months ended September 30, 2026 compared to the prior year period, interest decreased $80 and $445 of extinguishment charges that occurred in the prior year period from the Senior Secured Credit Facility; which was repaid in September 2025. These decreases were offset by interest expense of $8 related to the NCSU Promissory Note.

​

For the nine months ended September 30, 2026 compared to the prior year period, interest decreased $848 and $573 of extinguishment charges that occurred in the prior year period from the Senior Secured Credit Facility; which was repaid in September 2025. In addition, other interest expense charges decreased by $5 offset by an increase of $30 related to the NCSU Promissory Note.

​

​

Liquidity and Capital Resources

We have incurred significant losses and negative cash flows from operations since inception and expect to incur additional losses until such time that we can generate significant revenue and profit in our tobacco business. We had negative cash flow from operations of $8,636 for the nine months ended September 30, 2026 and an accumulated deficit of $408,325 as of September 30, 2026. As of September 30, 2026, we had cash and cash equivalents of $3,911 and working capital from continuing operations of $7,974 (compared to working capital from continuing operations of $10,359 at December 31, 2025). Given our projected operating requirements and existing cash and cash equivalents, there is substantial doubt about our ability to continue as a going concern through one year following the date that the Condensed Consolidated Financial Statements herein are issued.

33

Table of Contents

In response to these conditions, management is currently evaluating different strategies for reducing expenses, as well as pursuing financing strategies which include raising additional funds through the issuance of securities, asset sales, and through arrangements with strategic partners. If capital is not available to the Company when, and in the amounts needed, it could be required to liquidate inventory or assets, cease or curtail operations, seek to negotiate new business deals with our business partners or seek protection under applicable bankruptcy laws or similar state proceedings. There can be no assurance that the Company will be able to raise the capital it needs to continue operations and, if we are delisted from Nasdaq, we may not be unable to raise any capital. Accordingly, there is substantial doubt regarding our ability to continue in operations. Management’s plans do not alleviate substantial doubt about the Company’s ability to continue as a going concern through one year following the date that the Condensed Consolidated Financial Statements are issued.

Our cash and cash equivalents and working capital from continuing operations as of September 30, 2026 and December 31, 2025 are set forth below:

​

​

​

​

​

​

​

​

​

​

September 30

​

December 31

​

  ​ ​ ​

2026

  ​ ​ ​

2025

Cash and cash equivalents

​

$

3,911

​

$

7,149

Working capital

​

$

7,974

 

$

10,359

​

Working Capital

As of September 30, 2026, we had working capital from continuing operations of approximately $7,974 compared to working capital of approximately $10,359 at December 31, 2025, a decrease of $2,385. This decrease in working capital was primarily due to a decrease in net current assets of $3,367 offset by a decrease in net current liabilities of $982. Cash and cash equivalents decreased by $3,238 and the remaining net current assets decreased by $129. Management remains committed to pursuing further initiatives to optimize liquidity. Refer below to “Cash demands on operations.”

Summary of Cash Flows

​

​

​

​

​

​

​

​

​

​

​

Nine Months Ended

​

​

​

​

September 30, 

​

Change

​

  ​ ​ ​

2026

  ​ ​ ​

2025

​

$

Cash provided by (used in):

​

​

​

​

​

​

​

​

Operating activities

​

$

(8,636)

​

$

(10,472)

​

1,836

Investing activities

​

 

(715)

 

 

150

​

(865)

Financing activities

​

 

6,113

 

 

10,746

​

(4,633)

Net change in cash and cash equivalents

​

$

(3,238)

 

$

424

​

(3,662)

​

Net cash used in operating activities

Cash used in operating activities decreased $1,836 from $10,472 in 2025 to $8,636 in 2026. The primary driver for this change was a decrease in cash used for working capital components related to operations in the amount of $10,389, offset by higher net loss of $7,154 and a decrease of $1,399 related to net adjustments to reconcile net loss to cash for the nine months ended September 30, 2026, as compared to the nine months ended September 30, 2025.

Net cash used in (provided by) investing activities

Cash used in investing activities amounted to $715 for the nine months ended September 30, 2026, as compared to cash provided by investing activities of $150 for the nine months ended September 30, 2025. The decrease in cash provided by investing activities of $865 was the result of $770 of proceeds from the sale of property, plant and equipment primarily from the sale of Needlerock farms that occurred in the prior year period, $500 from the issuance of the GVB promissory note in the prior year, $25 received from the 2025 GVB promissory note in the current year period and an increase of cash outflows of $620 related to the acquisitions of patents, trademarks, licenses and property, plant and equipment.

34

Table of Contents

Net cash provided by financing activities

During the nine months ended September 30, 2026, cash provided by financing activities decreased by $4,633 compared to $10,746 in the prior year period to $6,113 in the current year period, resulting from decreases in cash inflows of (i) $221 for proceeds from issuance of note payable, (ii) $2,766 of net proceeds of warrant exercises, and (iii) $9,893 of net proceeds from Series A convertible preferred stock that occurred in the prior year period offset by cash inflows of (a) net proceeds from Series B convertible preferred stock issuances of $15,299 and (b) $64 for net proceeds from issuance of common stock related to the ATM. Cash outflows increased in the current year period by the redemption of Series A at par value of $9,650, redemption of Series B at par value of $2,010, and principal payments for finance leases of $12 offset by decreases from payments on long-term debt of $4,336 and notes payable of $220.

Cash demands on operations

We have financed our operations to date primarily through the issuance of equity securities, proceeds from the exercise of warrants to purchase common stock and sale of debt instruments with various institutions, accredited investors, high net worth individuals and creditors.

​

In March 2026, we issued 16,000 shares of Series B convertible preferred stock and 4,026 warrants to purchase shares of common stock for net proceeds of $15,275, of which $9,650 was used to repurchase at par all of the remaining shares of outstanding Series A convertible preferred stock issued in August 2025. The investors from the Series B convertible preferred stock offering have an additional 4,000 shares that may be purchased at subsequent closings, of which 25 shares have been purchased through September 30, 2026.

In June 2026, we received net proceeds of $2,309 from the inducement and exercise of 4,615 existing warrants for shares of common stock and issuance of 4,609 warrants to purchase common stock. The Company utilized a portion of the net proceeds to repurchase at par 2,010 shares of Series B convertible preferred stock in the amount of $2,010.

​

Subsequent to quarter-end, as outlined below, we received net proceeds of $10,138 from the sale of common stock pursuant to our at-the-market equity offering, of which approximately $4,562 of net proceeds was added to the Company’s cash position for ongoing operations and $5,576 of the net proceeds was utilized to repurchase at par 5,576 shares of Series B convertible preferred stock.

​

Outstanding Warrants

​

On August 13, 2026, the Company entered into an amendment with the holders of all of the outstanding June 2026 Inducement Warrants whereby the exercise price was reduced to $21.32 and to allow all of the June 2026 Inducement Warrants to be exercised on a cashless basis. Following the amendment, all 52,062 warrants were exercised on a cashless basis for an aggregate of 47,285 shares of common stock. Following the exercise, no warrants remain outstanding.

​

ATM Offering

​

We entered into a sales agreement (the “Sales Agreement”) which permits us to sell up to $25,000 of our common stock from time to time at prevailing market prices, which program was reduced to a maximum of $6,400 on May 1, 2026. No sales have occurred under the ATM program for the three months ended September 30, 2026. During the nine months ended September 30, 2026, the Company sold 42 shares of common stock under the ATM Program for gross proceeds of $200. The Company paid fees to the Sales Agent in the amount of $6.

​

35

Table of Contents

Subsequently on October 23, 2026, the Company filed a prospectus supplement permitting the sale of up to $18,800 shares of the Company’s common stock in its at-the-market offering pursuant to its sales agreement, as amended. The remaining capacity as of November 13, 2026 is approximately $13,000. The following table summarizes the Company’s common stock issuances under the ATM program as of November 13, 2026:

​

​

​

​

Number of common shares issued

​

​

3,151,300

Weighted average sale price per share

​

$

3.34

Gross proceeds

​

$

10,536

Net proceeds

​

$

10,138

​

The Company used $5,576 of net cash proceeds from the offering to repurchase an equal amount of Series B convertible preferred shares at par.  The remaining number of Series B convertible preferred shares outstanding after redemptions is 2,929.

​

Critical Accounting Policies and Estimates

​

The preparation of our Condensed Consolidated Financial Statements in accordance with accounting principles generally accepted in the U.S. requires management to make estimates, assumptions and judgments that affect the amounts reported in the financial statements and accompanying notes. Our estimates, assumptions and judgments are based on historical experience and various other assumptions believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying amount of assets and liabilities that are not readily apparent from other sources. Making estimates, assumptions and judgments about future events is inherently unpredictable and is subject to significant uncertainties, some of which are beyond our control. Management believes the estimates, assumptions and judgments employed and resulting balances reported in the Condensed Consolidated Financial Statements are reasonable; however, actual results could differ materially.

​

There have been no material changes to the information set forth in our Annual Report on Form 10-K for the year ended December 31, 2025.

​

Off-Balance Sheet Arrangements

​

We do not have any off-balance sheet arrangements as defined by Item 303(a)(4) of Regulation S-K.

​

​

Item 3. Quantitative and Qualitative Disclosures about Market Risk

There have been no material changes to the information set forth in our Annual Report on Form 10-K for the year ended December 31, 2025.

Item 4. Controls and Procedures

(a)

Evaluation of Disclosure Controls and Procedures:

The Company maintains disclosure controls and procedures that are designed to ensure that information required to be disclosed in its Securities Exchange Act of 1934 (“Exchange Act”) reports are recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms, and that such information is accumulated and communicated to the Company’s management, including the Company’s chief executive officer and chief financial officer, as appropriate, to allow timely decisions regarding required disclosure. Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures.

36

Table of Contents

Our chief executive officer and chief financial officer, after evaluating the effectiveness of the Company’s “disclosure controls and procedures” (as defined in the Exchange Act Rules 13a-15(e) or 15d-15(e)) as of the end of the period covered by this quarterly report, have concluded that our disclosure controls and procedures were effective as of the end of the period covered by this Form 10-Q to ensure information required to be disclosed is recorded, processed, summarized and reported within the time period specified by SEC rules, based on their evaluation of these controls and procedures as required by paragraph (b) of Exchange Act Rules 13a-15 or 15d-15.

(b)

Changes in Internal Control over Financial Reporting:

There were no changes in our internal control over financial reporting during the quarter ended September 30, 2026 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

​

37

Table of Contents

​

Part II. OTHER INFORMATION

Item 1. Legal Proceedings

See Note 12 - Commitments and Contingencies – Litigation - to our Condensed Consolidated Financial Statements included in this Quarterly Report for information concerning our on-going litigation. In addition to the lawsuits described in Note 12, from time to time we may be involved in claims arising in the ordinary course of business. To our knowledge other than the cases described in Note 12 to our Condensed Consolidated Financial Statements, no material legal proceedings, governmental actions, investigations or claims are currently pending against us or involve us that, in the opinion of our management, could reasonably be expected to have a material adverse effect on our business and financial condition.

​

Item 1A. Risk Factors

Except as set forth below, there have been no material changes from the risk factors disclosed in Item 1A of Part I of our Annual Report on Form 10-K for the year ended December 31, 2025, as filed with the SEC on March 26, 2026, and in Item 1A of Part II of our Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2026, as filed with the SEC on August 14, 2026.

Nasdaq may delist our common stock from trading on its exchange, which could limit investors’ ability to make transactions in our common stock, negatively impact the liquidity of our common stock and materially impair our ability to raise the additional capital necessary to continue our operations.

Our common stock is currently listed on the Nasdaq Capital Market (“Nasdaq”). To maintain that listing, we must satisfy Nasdaq’s continued listing requirements, including requirements relating to the minimum bid price of our common stock, the market value of our listed securities, stockholders’ equity, the market value of our publicly held shares, the number of publicly held shares and public holders, corporate governance and other matters. We cannot assure you that we will continue to satisfy all applicable Nasdaq continued listing requirements.

Currently, our stock price has closed under $1.00 for the 1 trading days prior to the date hereof. Under Nasdaq Listing Rule 5550(a)(2), the closing bid price of our common stock generally must be at least $1.00 per share. If the closing bid price is below $1.00 per share for 30 consecutive business days, Nasdaq may notify us that we no longer comply with the minimum bid-price requirement. Although Nasdaq’s rules usually provide an eligible company with a compliance period in which to regain compliance, we may not qualify for an automatic compliance period due to prior reverse stock splits, but may receive an extension following a hearing with Nasdaq. Regaining compliance may require the closing bid price of our common stock to equal or exceed $1.00 per share for a specified number of consecutive business days, and Nasdaq may require a longer compliance period in its discretion.

During the past two years, we have received deficiency letters from the Nasdaq Listing Qualifications Department notifying us that we were not in compliance with certain Nasdaq continued listing requirements. Although we addressed those deficiencies and regained compliance, our prior compliance does not provide assurance that we will maintain compliance in the future. We may receive additional deficiency or delisting notices, and any compliance period or exception available under Nasdaq’s rules may be insufficient for us to regain compliance. Nasdaq may also amend its listing standards, adopt more stringent standards or alter the remedies available to a company that fails to comply.

If Nasdaq delists our common stock from trading on its exchange, we could face significant material adverse consequences, including:

●limited availability of market quotations for our common stock;

●reduced ability to raise capital;

●reduced liquidity with respect to our securities;

38

Table of Contents

●a determination that shares of our common stock constitute “penny stock,” which would require brokers trading in our shares to comply with more stringent rules and could result in a reduced level of trading activity in the secondary trading market for our shares;

●a limited amount of news, securities-analyst and institutional-investor coverage;

●increased price volatility and wider bid-and-ask spreads;

●the possible loss of confidence by investors, employees, customers, suppliers and other business partners;

●reduced ability of investors to dispose of their shares or obtain accurate quotations regarding the market value of our common stock; and

●a decreased ability to issue additional common stock, use our securities as acquisition consideration or obtain additional financing in the future.

A delisting or trading suspension could also materially impair our ability to raise capital. We have incurred significant losses and may require additional capital to fund our operations, satisfy our obligations, execute our business strategy and continue as a going concern. Investors may be unwilling to purchase our securities if they are not listed on a national securities exchange, and any financing that remains available may involve substantially higher costs, more restrictive terms, significant discounts, warrant coverage, senior or secured securities, or substantial dilution to existing stockholders. Delisting could also impair our ability to use an effective registration statement, access at-the-market or other public equity programs, or satisfy exchange-related conditions in existing or future financing agreements.

The occurrence of any of these events could materially and adversely affect the value and liquidity of our common stock, our business, financial condition and results of operations, and our ability to continue as a going concern.

​

​

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.

None that were not previously disclosed in a Current Report on Form 8-K.

​

​

Item 3. Default Upon Senior Securities.

None

​

Item 4. Mine Safety Disclosures

None

​

Item 5. Other Information

During the three months ended September 30, 2026, there were no modifications, adoptions or terminations by any directors or officers to any contract, instruction or written plan for the purchase or sale of securities of the Company that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) or non-Rule 10b5-1 trading agreements.

​

​

39

Table of Contents

Item 6. Exhibits

​

Exhibit 31.1

Section 302 Certification - Chief Executive Officer

 

 

Exhibit 31.2

Section 302 Certification - Chief Financial Officer

 

 

Exhibit 32.1

Certification of Chief Executive Officer and Chief Financial Officer pursuant to 18 U.S.C. Section 1350 as adopted pursuant to section 906 of the Sarbanes-Oxley Act of 2002.

 

 

101.INS

Inline XBRL Instance Document

 

 

101.SCH

Inline XBRL Taxonomy Extension Schema Document

 

 

101.CAL

Inline XBRL Taxonomy Extension Calculation Linkbase Document

 

 

101.DEF

Inline XBRL Taxonomy Extension Definition Linkbase Document

 

 

101.LAB

Inline XBRL Taxonomy Extension Label Linkbase Document

 

 

101.PRE

Inline XBRL Taxonomy Extension Presentation Linkbase Document

​

​

Exhibit 104

Cover Page Interactive Data File (formatted as Inline XBRL)

​

​

​

​

​

​

​

​

40

Table of Contents

​

SIGNATURES

​

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized:

​

​

 

22nd CENTURY GROUP, INC.

 

 

Date: November 16, 2026

/s/ Lawrence D. Firestone

 

Lawrence D. Firestone

 

Chief Executive Officer

 

(Principal Executive Officer and Authorized Officer)

 

 

Date: November 16, 2026

/s/ Daniel A. Otto

 

Daniel A. Otto

 

Chief Financial Officer

 

(Principal Accounting and Financial Officer)

​

41

Keep reading